The Role of Glutaminase and Extracellular Vesicles in Macrophages and Microglia by Wu, Beiqing
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Theses & Dissertations Graduate Studies 
Summer 8-19-2016 
The Role of Glutaminase and Extracellular Vesicles in 
Macrophages and Microglia 
Beiqing Wu 
University of Nebraska Medical Center 
Follow this and additional works at: https://digitalcommons.unmc.edu/etd 
 Part of the Infectious Disease Commons, Nervous System Commons, Nervous System Diseases 
Commons, and the Neurology Commons 
Recommended Citation 
Wu, Beiqing, "The Role of Glutaminase and Extracellular Vesicles in Macrophages and Microglia" (2016). 
Theses & Dissertations. 121. 
https://digitalcommons.unmc.edu/etd/121 
This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It 
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
The Role of Glutaminase and Extracellular Vesicles in Macrophages and 
Microglia 
 
By 
 
Beiqing ‘Mercury’ Wu 
 
 
 
A DISSERTATION 
Presented to the Faculty of  
The Graduate College in the University of Nebraska 
In Partial Fulfillment of the Requirements 
For the Degree of Doctor of Philosophy 
 
Department of 
Pharmacology and Experimental Neuroscience 
 
Under the Supervision of Dr. Jialin Zheng 
Medical Center 
Omaha, Nebraska 
June, 2016 
The Role of Glutaminase and Extracellular Vesicles in Macrophages and 
Microglia 
 
Beiqing ‘Mercury’ Wu, M.D. Ph.D. 
University of Nebraska, 2016 
Advisor: Jialin Zheng, M.D. 
Glutamate serves as a crucial excitatory neurotransmitter that is essential 
for the proper functioning of the brain. However, excess levels of glutamate are 
neurotoxic and contribute to the pathogenesis of various neurodegenerative 
diseases, inducing HIV-1 associated neurocognitive disorders (HAND). 
Glutaminase 1 (GLS1) is an important mitochondrial enzyme responsible for 
producing glutamate from glutamine. GLS1 is upregulated during HAND and 
released from mitochondria to cytosol and extracellular space. However, why and 
how GLS1 is released remains unknown. In chapter II, we demonstrated that 
extracellular vesicles (EVs) carry GLS1 as cargos from cytosol to extracellular 
space during HIV infection and innate immune activation. The GLS-containing 
EVs induce neurotoxicity through the overproduction of glutamate, implicating the 
pathogenic role of EVs and GLS1 in HAND.  
Regulation of EV remains to be fully elucidated in HAND. Interestingly, 
when carried as cargo, GLS1 showed a potential effect on the release of EV. 
Therefore, we hypothesize that the release of EV is dependent on GLS1-
mediated glutamine and sphingolipid metabolism. In chapter III, we investigated 
the involvement of GLS1 in EV release in GLS1-overexpressing HeLa cells, HIV-
1-infected macrophages, and immune-activated microglia through the use of 
GLS1 inhibitors. In the aforementioned cell types, GLS1 inhibitor significantly 
decreased the level of EVs, suggesting an important role of GLS1 in EV 
regulation. In chapter IV, we further investigated the mechanism of GLS1-
mediated EV release. We identified that GLS1-mediated EV release is 
dependent upon the level of glutamine and a-ketoglutarate (a-KG). Because 
a-KG is an important metabolite of glutamate, these data suggest that a-KG is an 
essential GLS1 downstream factor that regulates the release of EVs. Biogenesis 
of EVs requires the sphingolipid ceramide. However, it is unknown whether 
GLS1-mediated EV release involves ceramide. We have demonstrated that the 
addition of ceramide rescued the suppression of EV release by GLS1 inhibitors, 
suggesting that GLS1 mediates EV release through ceramide. 
In summary, our data revealed two interesting insights into the biology of 
EVs. First, GLS-containing EVs is a pathogenic component of neurodegeneration 
in HAND. Second, the release of EVs is dependent on GLS1-mediated glutamine 
and sphingolipid metabolism. Studies on both of these aspects in EVs could lead 
to potential novel therapeutic targets for HAND and other neurodegenerative 
diseases. 
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1.1 HIV-1 associated neurocognitive disorders 
1.1.1 Clinical manifestation 
 As reported by UNAIDS in 2014 (UNAIDS), approximately 35 million 
people worldwide are infected with Human Immunodeficiency Virus (HIV), which 
continues to cause significant morbidities [1]. Among the cases of HIV infection, 
more than 90% of the global HIV pandemic attributes to HIV-1 infection but not 
HIV-2 [2]. 
 In addition to immune compromise, HIV infection causes a wide spectrum 
of HIV-1-associated neurocognitive disorders (HAND), which range from mild 
cognitive disease to dementia, even under the treatment of successful anti-
retroviral therapy [3, 4]. HAND is characterized by cognitive deteriorations, 
behavioral impairments and motor function loss due to progressive neuronal 
damage. HAND consists of three major classifications based on guidelines in the 
measurements of cognitive dysfunction: HIV-1 associated dementia (HAD), mild 
neurocognitive disorder (MND), and asymptomatic neurocognitive impairment 
(ANI) [4-6]. Thanks to the effective treatment of highly active antiretroviral therapy 
(HAART), the prevalence of the most severe form of HAND, HAD has been 
dramatically reduced [7]. However, the incidence of the moderate and mild forms 
of HAND remains high and cannot be ignored [7-9]. Recent reports have shown 
that the increasing resistance to the antiretroviral drug can be caused to the 
following reasons: the increasing viral mutation, the increasing lifespan of HIV-
infected individuals, and the compromised blood-brain barrier (BBB) disturbed by 
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HAART [10-12]. Mononuclear phagocytes, including macrophages and microglia, 
are found to be HIV reservoirs [7, 13, 14]. 
 The quality of life for HIV individuals is significantly affected because of 
the difficulty in obtaining employment due to discrimination/disease burden and a 
decreased ability to perform complex daily tasks due to HAND. Examples of 
impairments include finance management and housekeeping, and poor quality of 
life and poor compliance to medical instructions [4, 15-18]. Despite peripheral 
control of HIV replication by HAART, 60% - 90% of the individuals have a certain 
degree of cognitive disease [1, 19]. 
 
1.1.2 Pathobiology of HAND 
 HIV-1 associated dementia is the most severe form of HAND, which is a 
chronic disease state in progressive HIV-1 infection with HIV encephalopathy or 
AIDS dementia complex [7, 20]. During HIV-1 infection, HIV virus infects 
circulating monocyte/macrophages and enters the central nervous system (CNS) 
within weeks after the initial infection through a ‘Trojan horse’ mechanism, which 
impairs the cognition including attention, memory, language, problem solving and 
decision making [1, 20]. The other symptoms of HAND include confusion, 
forgetfulness, behavioral changes, headaches, gradual weakening and loss of 
falling in the arms and legs, problems with cognition or movement and pain due 
to nerve damage (NIH) [21-23].  
 HAND correlates with HIV-1 encephalitis (HIVE) histologically [24]. 
Studies with in situ hybridization indicate that productive HIV-1 infections appear 
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exclusively in perivascular monocyte-derived macrophages (MDM) [25-27]. The 
post-mortem pathology reports from HAD patient brain sections show 
progressive infection and infiltration of perivascular MDM, which results in the 
formation of multinucleated giant cells [26, 27]. Activated perivascular 
macrophages activate astrocytes and lead to reactive astrogliosis, myelin pallor 
and white mater diffusion, reduction in synaptic density, increased BBB 
permeability, and neuronal damage or loss [21, 28]. 
 In the pre-HAART era, approximately 40% reduction in neuronal densities 
in the frontotemporal cortex [21, 29], and 50%-90% reduction in neuronal 
densities in the hippocampus were reported [30]. Highly regulated cell death, 
known as apoptosis, was believed to be the major cause of neuronal loss. 
Recent observations of samples from HAND patients with treatment of HAART 
still showed decrease of neuronal loss and further neuronal damage [31-33]. The 
neuronal damage in the areas of the brain such as basal ganglia, cerebral cortex, 
and hippocampus in HAND patients’ causes significant cognitive impairment [34].  
 HIV majorly infects brain microglia and macrophages. Infection of 
astrocytes is restricted because of the lack of CD4 presence on the cells [35-38]. 
Although neurons are not susceptible to HIV, neurons are largely affected by the 
HIV-infected neighboring cells in the CNS [39, 40], such as HIV-infected 
astrocytes, macrophages and microglia, due to the production of viral proteins, 
cytokines and neurotoxins [41-46]. The elevation of these neurotoxic factors 
contributes to the damage of synapses, impairment of neuronal function and 
chronic inflammation. This leads to the disruption of the connections of the 
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neuronal network and impaired neurotransmission, and thus causes 
neurodegeneration [47-51]. Studies show that the viral proteins released by 
infected macrophages and microglia further infect uninfected cells in the CNS, 
and release a variety of proinflammatory molecules and neurotoxins, which 
causes further neuronal damage and leads to more severe form of HAND [52, 
53]. 
 
1.2 Macrophage and microglia activation 
 Macrophages and microglia are mature mononuclear phagocytes (MPs) 
that are both crucial to the innate and adaptive immune responses. MPs engulf 
pathogens and cellular debris, process them into small peptides of 10-14 amino 
acids and present them onto the cell surface. Antigens can be presented to 
appropriate specific T cells receptor, which leads to a high-affinity interaction 
between antigen presenting cells (APC) and T N-Methyl-D-aspartic acid cells and 
initiates T cell activation. MPs stimulate the immune response through the 
production of inflammatory cytokines and chemokines, and further amplifying the 
immune response [54, 55]. 
 Both macrophages and microglia are believed to be pivotal in the 
pathogenesis of neurodegenerative disease, particularly HAND. During HAND, 
MPs infiltrated into the CNS through the BBB. There, MPs acquire enhanced 
phagocytic capability, secrete proinflammatory cytokines and chemokines, and 
release cytotoxic factors. All of these events lead to injury to bystander cells 
including neurons [48, 56]. In the past, there was controversy over whether or not 
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MPs express neurotrophic factors during brain inflammation or clear pathogens 
through phagocytosis. Recent studies have shown that MPs do perform both 
functions, and that these functions account for the pathogenesis of HAND. 
 During HAND, HIV establishes a latent and persistent infection within 
MPs, which serves as a viral reservoir and allows HIV to evade immune 
surveillance. HIV in the CNS primarily exists within the perivascular blood and 
parenchymal brain macrophages and microglia [41]. Neurons, astrocytes, 
oligodendrocytes and endothelial cells in the brain are barely infected by HIV [22, 
57, 58]. MPs are the major population that produces and releases a variety of 
neurotoxins into the brain [41-45, 59-62], including platelet activating factor [63-
65], arachidonic acid [66], pro-inflammatory cytokines and chemokines [67], 
quinolinic acid [68, 69], nitric oxide [70] and excess glutamate [71, 72]. MPs have 
been believed to be immune protective. However, MPs can also be responsible 
for tissue damage. The mechanism wherein activated MPs during HIV infections 
can induce neuronal injury remains to be elucidated.  
 
1.3 Excitotoxicity 
 Chronic neuroinflammation contributes to the major pathogenesis of 
neurodegenerative diseases including HAND, amyotrophic lateral sclerosis, 
multiple sclerosis, Parkinson’s disease and Alzheimer’s disease [48, 49, 51]. 
Brain inflammation has been suggested to be closely associated with neuronal 
injury [47, 73]. HIV infection and immune stimulation activate microglia and 
macrophages, which induce brain inflammation and neuronal damage via 
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production of a variety of soluble neurotoxic factors [70, 74] including viral 
proteins, platelet activating factors, proinflammatory cytokines and chemokines, 
nitric oxide, and excess glutamate [46, 50, 75-77]. In neurodegenerative 
pathology, the proinflammatory cytokines tumor necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β) are released in increasing concentrations, which induces 
neuronal damage via the excess release of glutamate [78].  
 Glutamate is one of the most important excitatory neurotransmitters and 
secondary messengers in the mammalian CNS [79, 80]. Glutamate plays a 
pivotal role in physiologic function regarding neural development, synaptic 
plasticity, learning and memory [81, 82]. Glutamate is packaged into presynaptic 
vesicles, which are recruited and docked to the release sites onto the dense 
electron active zones of presynaptic neurons [83]. After glutamate-containing 
vesicles are exocytosed into the synaptic cleft from the presynaptic nerve 
terminals with the intracellular calcium influxes, glutamate binds to glutamate 
receptors on the postsynaptic neurons [84-86]. The binding alters membrane 
potential of the postsynaptic neurons and thus the downstream signal 
transduction cascades.   
 There are three major downstream pathways of glutamate. First, 
glutamate is taken up by postsynaptic neurons for neuronal signal transmission. 
Second, glutamate can be taken up by presynaptic neurons through glutamate 
transporters. Third, the extra amount of glutamate in the synaptic cleft will be 
taken up by neighboring astrocytes through glutamate transporters at a sodium-
dependent mechanism [87-89].  
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 Studies also show that glutamate can potentially lead to extensive 
neuronal damage and excitotoxicity at excess level via the overactivation of 
glutamate receptors, which are N-Methyl-D-Aspartate (NMDA) receptors on 
neurons [90]. Neurotoxic viral proteins, such as HIV-1 coat protein glycoprotein 
120 (Gp120) and HIV trans-acting protein Tat, can induce modification of the 
kinetics of NMDA receptors located on postsynaptic neurons through the 
stimulation of the release of arachidonic acid from infected glial cells [91]. The 
increasing production of extracellular glutamate contributes to the overactivation 
of NMDA receptors and the calcium overload within neurons [92, 93]. Calcium 
has long been understood as one of the most important secondary messengers 
in neural signal transduction. When dysregulated, calcium leads to oxidative 
stress including increasing production of free radicals, disruption of redox 
balance, mitochondrial dysfunction, caspase activation and cell death [94]. It has 
been reported that memantine, a moderate-affinity glutamate receptor 
antagonist, can reverse HIV viral protein-induced calcium overload in neurons 
and apoptosis. The inhibition of NMDA receptor, dizocilpine (MK-801), reverses 
the excitotoxicity in neurons induced by glutamate, which confirms the 
importance of glutamate in excitotoxicity [95, 96].  
 Furthermore, during HIV infection, the ability of astrocytes to absorb the 
extra amounts of glutamate in the extracellular space is impaired due to the 
dysfunction of the glutamate transporters, which exacerbates the excess levels of 
glutamate and further induces excitotoxicity [97-101]. 
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 In summary, elevation in extracellular glutamate levels has been proven to 
be associated with the pathogenic processes of various CNS disorders and 
neurodegenerative diseases including HAND [72, 102-104]. 
 
1.4 Glutaminase 1 
 Glutaminase is a phosphate-activated amidohydrolase, which deaminases 
glutamine into glutamate in the mammalian CNS [105]. Two major types of 
glutaminase have been identified in mammals, kidney-type glutaminase and 
liver-type glutaminase. Kidney-type glutaminase, also known as glutaminase 1 
(GLS1) is the predominant enzyme to utilize glutamine to produce glutamate. 
GLS1 is a hetero-tetramer, located in the inner membrane of mitochondria. GLS1 
is found abundantly expressed in a variety of cells in CNS. Liver-type 
glutaminase, or glutaminase 2 (GLS2) is expressed at lower levels in the brain 
[106].  
 GLS1 and GLS2 are encoded by separate genes on different 
chromosomes. The human Gls1 gene is located on chromosome 2 and has two 
major isoforms attributed to tissue-specific alternative splicing [107, 108]. In a 
twist of confusing nomenclature, one of the isoforms of GLS1 is named kidney-
type glutaminase (KGA), while the other isoform is known as glutaminase C 
(GAC). These two splice variants of GLS1, are found abundantly in mammalian 
brain tissues [109]. KGA and GAC transcribe exons 1-14 in the N-terminal and 
share the same functional region of KGA from 230 to 550 AA. KGA and GAC 
have a unique C-terminal, respectively, where KGA transcribes exons 16-19 and 
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GAC transcribes exon 15 [109]. When glutamine is catalyzed by glutaminase into 
glutamate, glutamate is subsequently further catalyzed by glutamate 
dehydrogenase into α-ketoglutarate. Subsequently, α-ketoglutarate enters the 
tricarboxylic acid (TCA) cycle to manage the energy generation [110]. Therefore, 
the important metabolism of glutamine through GLS1 is critical to the generation 
of the neurotransmitter, glutamate, and the brain bioenergetics via the TCA 
cycles. 
 In the physiological conditions, GLS1 is found most abundantly in neurons 
and less so intense in astrocytes, microglia, and macrophages in the CNS. 
However, when microglia and macrophages are activated, the level of GLS1 is 
altered, which leads to the abnormal glutamate-glutamine cycle in the CNS. 
 
1.5 The pathological role of Glutaminase 1 in HAND 
 Although the exact mechanisms of how HIV infection induces HAND 
remains to be elucidated, the role of GLS1 has been reported to be crucial in the 
pathogenesis of HAND. In the past decade, our lab has helped to determine the 
neurotoxic profile of brain macrophages and microglia in cooperation with other 
researchers. We have been devoted to discovering novel molecular mechanisms 
and biochemical tools to understand the pathogenesis and a potential target for 
treating HAND.  
 Our group has identified that HIV-1 infected human macrophages and 
microglia express high levels of GLS1 that contribute to the production of excess 
extracellular glutamate, which leads to neurotoxicity through overstimulation of 
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NMDA receptors. Notably, HIV-infected macrophages and microglia show 
upregulated GLS1 that produces increasing levels of glutamate dependent on 
glutamine, which indicates that the increasing level of GLS1 can augment the 
neuroinflammation and neurotoxicity [53, 72]. We have also reported that HIV-1-
infected macrophages and microglia are the major sources of increased 
extracellular glutamate and that they are significantly more neurotoxic than the 
uninfected macrophages and microglia [53, 111, 112].  The major upregulated 
isoform of GLS1 in HIV-1-infected macrophages and microglia is GAC, both at 
the RNA and protein levels, not KGA. Using siRNA to target GLS1 in HIV-1-
infected macrophages and microglia significantly reduces the production of 
glutamate and the associated toxicity in neurons. Removing the glutamine, 
antagonizing the NMDA receptor, or blocking GLS1 activity by pharmacological 
GLS1 inhibitors effectively reversed the excess generation of glutamate and 
neurotoxic effects from HIV-1-infected macrophages and microglia [53]. In the 
samples of postmortem HAND patients’, increasing levels of glutamate and 
upregulated GLS1 are found in vivo, which also proves the importance of GLS1 
in the pathogenic process and disease progressions of HAND. 
  Mitochondrial oxidative stress is caused by the infection of HIV-1, which 
mediates the release of GLS1 from the inner membrane of mitochondria to 
cytosol through the permeability transition pore [111]. Interestingly, we also 
detected the release of GLS1 in the extracellular media. However, the 
mechanism of release of GLS1 from cytosol to extracellular media remains 
unknown.  
  12 
 The expression of GLS1 is usually most abundant in neurons. However, 
little has been known about the role of GLS1 in mediating the excitotoxicity in 
neurons associated with HAND until recently. In our laboratory, we reported that 
treatment of IL-1β and TNF-α, the two proinflammatory cytokines typically 
elevated during neurodegenerative conditions, on neurons induces cell apoptosis 
through substantially increased intracellular and extracellular glutamate levels 
[78]. The glutamate produced from these neurons under inflammation induces 
toxicity in other neurons. Furthermore, IL-1β and TNF-α upregulates the 
expression of the GLS isoform KGA expression in human neurons and increases 
the release of KGA from the mitochondria into the cytosol. TNF-α also triggers 
the release of GLS1 into the extracellular space. We also found that Interferon 
α/β (IFN-α/β), generated from HIV-1-infected macrophage/microglia, activates 
Signal transducer and activator of transcription 1 (STAT1) to bind with 
glutaminase promoters and regulate GLS1 expressions [113]. The neurotoxicity 
is reversed by the inhibition of GLS1 activity with pharmacological inhibitors or by 
the blockage of NMDA receptors with antagonists.  
 Taken together, these results indicate the critical role of dysregulated 
GLS1 in neurons, macrophages, and microglia in the pathogenesis of brain 
inflammation and HAND. 
 
1.6 Extracellular vesicles 
 Extracellular vesicles (EVs) have been implicated in various 
neurodegenerative diseases and neuroinflammation including Alzheimer’s 
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disease, Parkinson’s disease, prion disease, Huntington’s disease, multiple 
sclerosis, and HAND. EVs are vesicles ranging from 30 nm to 1000 nm that are 
shed from various cell types including neurons, astrocytes, macrophages, 
microglia, oligodendrocytes and blood endothelial cells in the CNS. EVs are 
released under normal and pathological conditions. EVs are composed of 
microvesicles (MVs) and exosomes, in which MVs range from 100 nm to 1000 
nm while exosomes range from 30 nm to 100 nm. Biologically, MVs are believed 
to be derived from the plasma membrane, while exosomes are thought to be 
derived from the inward budding of the late endosomes. After budding, they are 
held within multivesicular bodies, which fuse with the plasma membrane. Both 
MVs and exosomes were once considered as a mechanism for discarding 
cellular debris or material. However, attention has been drawn to the role of EVs 
in the importance of intercellular communication and signal transduction. 
Evidence has shown that EVs can carry, nucleic acids, mRNAs, and other 
noncoding RNAs, proteins, cytokines and lipids among cells. Since differentiating 
exosomes and MVs is still a big challenge, the entire population of secreted and 
released MVs and exosomes in the extracellular milieu are all identified as EVs. 
Due to the various intracellular origins and formation of EVs, the detailed 
functional role of EVs under normal and disease conditions warrants further 
investigation. 
 The biogenesis of EVs including microvesicles and exosomes is still under 
investigation. Exosomes are believed to originate in the endocytic pathway, 
where proteins are internalized, and are either recycled back to the plasma 
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membrane or sorted for degradation [114, 115]. After internalization, early 
endosomes are formed and mature into late endosomes with an inward budding 
of their membrane and accumulation of intraluminal vesicles (ILVs) to form 
multivesicular bodies (MVBs). MVBs either fuse with lysosomes for degradation 
of their contents, or fuse with the plasma membrane to release the exosomes to 
the extracellular milieu via exocytosis [116-118]. However, it remains to be 
elucidated how pathway selection is determined. The biogenesis of microvesicles 
also needs further investigation.  
 As a mixture group of proteins, lipids and other cytosolic molecules is 
sorted into exosomes and microvesicles, the specific contents of EVs can vary 
depending on the type of cells, the condition of the cells, and the 
microenvironment niche the cells are in. There has been increasing interest in 
EVs and studies have focused on building the databases of the contents of EVs 
from different physiologic environments, which is continuously updated in 
Exocarta, Vesiclepedia and EVpedia [119-121]. In these database, different 
proteins, lipids, mRNAs, and miRNAs are identified in EVs from different cells 
types and organisms by proteomics, mass spectrometry and microarray. Studies 
show that EVs contain proteins from endosomes, plasma membrane, and cytosol 
that are involved in MVB biogenesis, membrane associated proteins, 
transmembrane proteins, cytoskeletal proteins, signal transduction proteins, 
chaperones and metabolic enzyme, but few from nuclei, Golgi, endoplasmic 
reticulum (ER) and mitochondria [119, 122, 123]. Among these proteins, there is 
an overlap of important proteins between microvesicles and exosomes, which 
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makes it a challenge to find individual specific markers. EVs are also enriched in 
lipid composition such as ceramide, cholesterol, sphingomyelin, and 
phosphatidylserine, which provides a tool and a recipe for artificial liposome 
formulation to mimic the EVs [124]. However, due to the complexity and 
variability of EVs, there are still limitations to overcome in liposomes synthesis. 
Additionally, miRNAs of 20-22 nucleotides have been associated with EVs. 
These miRNAs target the 3’ untranslated region of specific mRNAs to inhibit their 
translation, which affects the proliferation, differentiation, survival and function of 
the cells [125]. Despite the variety of cellular contents in the EVs, questions 
remain as to mechanisms of cargo incorporation into EVs are, and how they are 
altered dependent on the cell source and the physiological or pathological 
condition and microenvironment of the cells [126, 127].  
 EVs were believed to be a pathway to degrade unwanted cellular 
contents, however, the recent hypotheses focus more on their role in cargo 
delivery, and intercellular signaling, especially during immune responses [128, 
129]. While more light has been shed on the role of EVs in several cancers; 
however, further investigation is needed on their role in the CNS system. 
 Recent studies have indicated the importance of EVs in translational 
research, since it is know that EVs can be detected in biological fluids, such as 
blood, plasma, urine, and CSF [130-132]. It has been suggested that EVs have 
been used as biomarkers for various diseases. The contents in the EVs detected 
from CSF-samples reflect brain physiology, including amyloid precursor protein 
(APP) and amyloid β (Aβ) in Alzheimer’s disease, α-synuclein  in 
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Parkinson's disease, PrPsc in prion disease, and Superoxide dismutase (SOD) in 
amyotrophic lateral sclerosis.  
 
1.7 Mechanism of extracellular vesicle release 
 The mechanisms of detailed differentiation of EVs is still understudied. 
There are a few major hypotheses about the EV release. One of these is called 
Endosomal Sorting Complexes Required for Transport (ESCRT) machinery, 
which involves the ESCRT complexes and their associated proteins [133]. One of 
the alternative mechanisms is the ESCRT-independent pathway. This lipid-driven 
mechanism of EV release depends on the synthesis of ceramide from 
sphingomyelin by neutral sphingomyelinase [134]. Another hypothesis is the 
RhoA-dependent pathway, which has been suggested in EVs studies in cancer 
research [135]. 
 Despite the recent studies of the extracellular vesicles, very little is known 
about the mechanisms of EV release in macrophages and microglia. The role of 
GLS1 in the regulation of EVs remains to be further explored. 
  
1.8 Conclusion 
 Regarding the need to better understand HAND pathogenesis, we have 
learned that EVs contribute to the neuronal damage associated with 
overproduction of glutamate and excitotoxicity. The critical role of EV as the 
specific molecular cargo carriers and their place in intercellular communication 
cannot be ignored. Previous reports from the lab have shown the importance of 
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GLS1 and glutamate in HAND, and further investigation revealed the role of EVs 
in the release of GLS1 and the potential neurotoxic role of EVs during HIV-1 
infection and immune activation. In this case, we discovered a GLS1 inhibitor, 
and we are in the process of developing new inhibitors to rescue the GLS1-
mediated neurotoxicity, which can be a novel therapeutic strategy. 
 With the heated discussion about EVs, their contents, biogenesis, delivery 
and functions still require further investigations. During our study, we discovered 
an interesting phenomenon in that the inhibition of GLS1 could disrupt the 
formation or release of EVs to the extracellular space. This provides us with a 
new perspective on the important role of GLS1 in the biogenesis of EVs. This 
evidence can also be applied to the fields outside of neuroscience study, such as 
cancer research due to the important role of GLS1 in both fields. This 
observation can shed light on the correlation of glutamine metabolism and other 
pathways including sphingolipid biogenesis in EV release, which also indicates 
the importance of developing a new therapeutic strategy against EVs and GLS1.  
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1.9 Figures 
Figure 1.1 
 
Figure 1.1 proposed model for the pathogenic role dysregulated GLS1 and 
EVs in HAND. 
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Chapter 2 
HIV infection and immune activation induce neurotoxicity through GLS1-
containing extracellular vesicles 
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2.1 Abstract 
 HIV-1-infected and/or immune-activated microglia and macrophages are 
pivotal in the pathogenesis of HIV-1-associated neurocognitive disorders 
(HAND). Glutaminase, a metabolic enzyme that facilitates glutamate generation, 
is upregulated and may play a pathogenic role in HAND. Our previous studies 
have demonstrated that glutaminase is released to the extracellular fluid during 
HIV-1 infection and neuroinflammation. However, key molecular mechanisms 
that regulate glutaminase release remain unknown. Recent advances in 
understanding intercellular trafficking have identified extracellular vesicles (EVs) 
as a novel means of shedding cellular contents. We posit that during HIV-1 
infection and immune activation, microvesicles may mediate glutaminase 
release, generating excessive and neurotoxic levels of glutamate.  
 EVs isolated through differential centrifugation from cell-free supernatants 
of monocyte-derived macrophages (MDM) and BV2 microglia cell lines were first 
confirmed in electron microscopy and immunoblotting. As expected, we found an 
elevated number of EVs, glutaminase immunoreactivities, as well as glutaminase 
enzyme activity in the supernatants of HIV-1 infected MDM and 
lipopolysaccharide (LPS)-activated microglia when compared with controls. The 
elevated glutaminase was blocked by GW4869, a neutral sphingomyelinase 
inhibitor known to inhibit EV release, suggesting a critical role of EVs in 
mediating glutaminase release. More importantly, EVs from HIV-1-infected MDM 
and LPS-activated microglia induced significant neuronal injury in rat cortical 
neuron cultures. The EV neurotoxicity was blocked by a glutaminase inhibitor or 
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GW4869, suggesting that the neurotoxic potential of HIV-1-infected MDM and 
LPS-activated microglia is dependent on the glutaminase-containing EVs.  
 These findings support EVs as a potential pathway/mechanism of 
excessive glutamate generation and neurotoxicity in HAND and therefore EVs 
may serve as a novel therapeutic target. 
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2.2 Introduction 
HIV-1-associated neurocognitive disorders (HAND) are currently prevalent 
in spite of major advances in combination anti-retroviral therapy. Therefore, novel 
therapeutic targets are required to be developed to treat the disease [5, 9, 71, 
136]. The HIV-1-infected and immune-activated mononuclear phagocytes (MPs, 
including macrophages and microglia) are critical to HAND pathogenesis, 
producing a variety of inflammatory and neurotoxic factors, including excess 
levels of the excitatory neurotransmitter glutamate [137, 138]. Glutamate is a 
major mediator of excitatory synaptic transmission and has a vital role in 
mediating learning and memory [139-141]. Early studies reported that the 
concentrations of glutamate in the plasma and cerebrospinal fluid were 
significantly higher in HIV-1-infected patients than in uninfected controls [142-
145]. Studies also showed that excessive levels of extracellular glutamate induce 
excitotoxicity and augment neuroinflammation and neuronal injury, which may 
play a role in the pathogenesis of HAND [74, 108, 146-149]. 
Glutaminase (GLS), a resident mitochondrial enzyme, is specialized in the 
de novo synthesis of the neurotransmitter glutamate [42, 105, 150-152]. Two 
major types of GLS exist in mammals, which include “kidney-type” GLS (GLS1) 
and “liver-type” GLS (GLS2) transcribed from different genes. GLS has also been 
found to be abundant in the brain tissue [108]. In the human brain, GLS1 has two 
allozymes: kidney-type glutaminase (KGA) [153] and glutaminase C (GAC) [154]. 
The allozymes are generated through tissue-specific alternative splicing from the 
same gene and have the identical core GLS1 enzyme domain but different 3’ 
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tails [109]. Our previous studies suggested that GAC and KGA are differentially 
upregulated in HAND brain samples, HIV-1-infected MPs and inflammatory 
neurons [53, 72, 78, 112, 137]. Increased extracellular levels of glutamate from 
activated MPs could cause excitotoxicity to neurons through NMDA receptor 
activation [53, 112]. Therefore, regulation of GLS1 isoforms is of importance to 
HAND research. A key molecular event associated with the elevation of 
glutamate is the release of GLS1 [72, 78, 112]. Although several early 
observations of GLS1 release were linked with cell death, more recent data from 
our lab suggested that mitochondrial stress could lead to membrane 
destabilization and relocation of GLS1 from the mitochondrial matrix to the 
cytosol through the permeability transition pore [111]. Because the further 
release of GLS1 into extracellular supernatants contributes to excess glutamate 
production, it is imperative to understand the molecular mechanism of cellular 
GLS1 release. 
 Recent evidence indicates that extracellular vesicles (EVs), cellular 
secretory vesicles, are shed from the plasma membrane and range from 100 nm 
to 1 µm in diameter [155]. Interestingly, EVs are abundant in the central nervous 
system (CNS) and are derived from multiple brain cell types, including neurons, 
microglia, oligodendrocytes, and astrocytes [156]. Therefore, there is a growing 
appreciation of the important role of EVs in regulating the brain microenvironment 
[157, 158]. CNS-derived EVs may contribute to neuroinflammation through 
secretion of signaling molecules, nucleic acids, lipids, and proteins, and may 
participate in inter- and intra-cellular communication [155, 159-164]. The release 
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of EVs is increased upon neural cancer progression, neuroinflammation, and 
acute neurological disorders [165-167]. EVs could serve as a useful biomarker 
for CNS diseases including ischemic stroke, multiple sclerosis, glioblastoma, and 
other neurological and neurodegenerative disorders. However, the role of EVs in 
the pathogenesis of neurodegenerative disorders, especially HAND, remains to 
be elucidated. In our current study, we identified EVs as a primary mechanism of 
GLS1 release, which subsequently mediates excess glutamate generation and 
neurotoxicity from HIV-1-infected macrophages and immune-activated microglia. 
The investigation of the function of GLS1-containing EVs is important for 
understanding a potentially pathological event in HAND, and it may provide 
possible therapeutic targets and a unique biomarker. 
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2.3 Materials and methods 
Culture, HIV-1 infection and LPS activation of macrophages and microglia 
Human peripheral blood-derived mononuclear cells were isolated through 
leukopheresis from healthy donors. Human macrophages were differentiated in 
Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma Chemical Co., St. Louis, MO) 
with 10% human serum, 50 µg/ml gentamycin, 10 µg/ml ciprofloxacin (Sigma), 
and 1,000 U/ml recombinant human macrophage colony-stimulating factor 
(MCSF) for 7 days. The HIV-1ADA strain was used to infect the macrophages and 
microglia at a multiplicity of infection (MOI) of 0.1 and 0.5, respectively. The HIV-
1ADA strain was originally isolated from the PBMCs of an HIV-infected patient with 
Kaposi’s sarcoma [168, 169]. MDM was infected with HIV-1ADA at a multiplicity of 
infection (MOI) of 0.05 virus/target cell. For mock-infection, MDM was incubated 
with the same volume of medium without the virus. After 24 hours, the culture 
medium was changed to remove any remnant virus. Seven days after HIV-1-
infection, the culture medium was changed to glutamine-free neurobasal medium 
for 24 h and supernatants were collected for subsequent RT-HPLC or Western 
blot analysis. BV2 cell lines were obtained from ATCC, and both cell lines were 
grown in DMEM with 10% fetal bovine serum and antibiotics. Lipopolysaccharide 
(LPS) (50 ng/ml) (Sigma) was used to immune activate BV2 cells for 24 h and 
supernatants were collected for HPLC and Western blot analysis.  
 
Rat cortical neuron cultures 
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Cerebral cortices were dissected from Sprague-Dawley rat (Charles River 
Laboratories International Inc., Wilmington, MA) between embryonic days 15 and 
17 and triturated with a pipet to generate cell suspension. The cell suspension 
was passed through a 70-µm nylon membrane (Becton Dickinson Labware, 
Franklin Lakes, NJ) and then plated at a density of 40,000 cells/well in 96-well 
plates pre-coated with 5 µg/ml poly-D-lysine. The cells were then cultured at 
37 °C in a 5% CO2 atmosphere for 7 days in neurobasal medium containing B27 
supplement (Life Technologies), 0.5 mM glutamine, 100 U/ml penicillin and 100 
µg/ml streptomycin.  
 
Ethics statement  
Primary rat cortical neuron (RCN) were prepared in accordance with 
ethical guidelines for care and use of laboratory animals set forth by the National 
Institutes of Health (NIH), with Institutional Animal Care and Use Committee 
(IACUC) #: 04-097-01; Monocytes were used in full compliance with the 
University of Nebraska Medical Center and NIH ethical guidelines, with the 
Institutional Review Board (IRB) #: 162-93-FB. We have the informed written 
consent from all participants involved in this study.                 
 
Isolation of EVs  
EVs were isolated from the supernatants of HIV-1-infected macrophages 
and LPS-activated microglia through differential centrifugations with or without 
neutral sphingomyelinases inhibitor GW4869 (Sigma) at different dosages, 2, 5 
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and 10 µM. Briefly, the supernatants were first centrifuged at 300 X g for 10 min 
to remove free cells, at 3,000 X g for 20 min to remove cellular debris and then 
10,000 X g for 30 min to remove free organelles. Lastly, EVs were collected by 
ultracentrifugation at 100,000 X g for 2 h at 4°C. To prepare EVs for Western blot, 
the EVs pellets were lysed in M-PER mammalian protein extraction reagent 
(Thermo Scientific, Pittsburgh, PA). For negative staining, EVs were fixed in 2% 
glutaraldehyde and 2% paraformaldehyde. For glutaminase activity assay and 
neurotoxicity, the EVs were resuspended in 1 ml of glutamine-free neurobasal 
medium.  
 
Negative staining and electron microscopy 
EVs were negatively stained with onscreen measurements. Briefly, EVs were 
fixed and then spread on the silicon monoxide and nitro-cellular film coated 
copper grid. The droplets of EVs were removed with filter paper, air-dried at room 
temperature and then subjected to transmission electron microscopy (TEM) (FEI 
Tecnai G2 Spirit TWIN). For the scanning electron microscope (SEM) (FEI 
Quanta 200), cells were fixed in 2% glutaraldehyde and 2% paraformaldehyde 
and point dried, mounted and coated with gold/palladium. The investigator in the 
EM core facility was blinded for image acquisition and quantification. 
 
Neurotoxicity assays 
Resuspended EVs were added to neuronal cultures for 48 h with or without 10 
µM of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (a 
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generous gift presented by Dr. Tsukamoto from Colorado State University) and 
cell viability was assessed by MTT assays in 96-well plates.  MTT (Sigma) was 
added to the cultures to a final concentration of 125 µg/ml. The plates were 
incubated for 30 minutes at 37 °C with 5% CO2 and the medium was aspirated. 
The insoluble formazan was solubilized in DMSO, and the concentrations were 
determined by optical density at 490 nm with an ELX808 densitometer (Bio-Tek 
Instruments, Winooski, and VT). MAP2 ELISA was performed on primary RCN 
cultures as previously described. Briefly, fixed neurons were blocked with 3% 
normal goat serum in phosphate buffered saline and incubated for 2 hours with 
antibodies against microtubule associated protein 2 (MAP-2) (Millipore-Chemicon 
International, Atlanta, GA), followed by the anti-mouse biotinylated antibody 
(Vector Laboratories, Burlingame, CA) for 1 hour. Avidin/biotin complex solution 
was added for 30 minutes, and then color was developed using TMB substrate 
(Sigma Chemical Co., St. Louis, MO) and terminated with 1 M sulfuric acid 
(Sigma Chemical Co., St, Louis, MO). The absorbance was read at 450 nm using 
a microplate reader (Bio-Rad Laboratories, Hercules, CA). For morphological 
data that demonstrated neuronal damage after exposed to the supernatant of 
HIV-1-infected macrophages or immune-activated microglia, MAP2 
immunostaining was examined by a Nikon Eclipse TE2000E fluorescent 
microscope and photographed by a digital camera (CoolSNAP EZ, Photometrics). 
All obtained images were imported into Image-ProPlus, version 7.0 (Media 
Cybernetics, Sliver Spring, MD) for quantifying levels of MAP2 staining. The 
assessors were blinded during image acquisition or quantification. 
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Western blot 
Protein concentrations were determined by Bradford protein assay. SDS PAGE 
separated proteins from whole cell and EV lysates. After electrophoretically 
transferred to polyvinyldifluoridene membranes (Millipore, Billerica, MA and Bio-
Rad, Hercules, CA).  Membranes were incubated overnight at 4 °C with 
polyclonal antibodies for GAC (Dr.N.Curthoys, Colorado State University, Fort 
Collins, CO), Alix (Santa Cruz Biotechnology, CA) and flotillin-2 (Cell Signaling 
Technology, Danvers, MA), followed by horseradish peroxidase-linked secondary 
anti-rabbit or anti-mouse secondary antibodies (Cell signaling Technology). 
Antigen-antibody complexes were visualized by Pierce ECL Western Blotting 
Substrate. For quantification of the data, films were scanned with a CanonScan 
9950F scanner and images were analyzed using the public domain NIH image 
program (developed at the U.S. National Institutes of Health and available on the 
internet at http://rsb.info.nih.gov/nih-image/). 
 
Analysis of glutamate and glutamine by RP-HPLC 
Glutamate levels were analyzed by reverse phase high performance liquid 
chromatography (RP-HPLC) using an Agilent 1200 liquid chromatograph and 
fluorescence detector as previously described [53] with a few modifications. The 
experiments utilized 4.6 × 75 mm, 3.5 µm ZORBAX Eclipse AAA analytical 
columns (Agilent). A gradient elution program was optimized for glutamate 
measurement with a flow rate 0.75 ml/min.  
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Statistical analysis 
Data are expressed as means ± SD unless otherwise specified. Statistical 
analysis was performed using Analysis of variance (ANOVA), followed by the 
Tukey-post-test for paired observations. Significance was determined by a p 
value < 0.05. All experiments were performed with cells from at least three 
donors to account for any donor-specific differences. Assays were performed at 
least three times in triplicate or quadruplicate within each assay. 
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2.4 Results 
HIV-1 infection and immune activation increase EV release from 
macrophages and microglia  
 Our previous studies have demonstrated that GLS1 is released to the 
extracellular fluid during HIV-1 infection and neuroinflammation [72, 78, 112]. 
However, key molecular mechanisms that regulate GLS1 release remain 
unknown. The recent discovery of EVs during HIV-1 infection in macrophages 
and dendritic cells offers an exciting possibility that GLS1 may be released 
through EV mechanism [155, 170]. We used scanning electron microscopy (SEM) 
to identify EVs that were in the process of budding from macrophages (Fig. 2.1A, 
B). To quantitatively evaluate EV release, two different techniques for EV 
detection were used. First, EVs were isolated from cultured monocyte-derived 
macrophages (MDM) supernatants by differential centrifugation. To reflect the 
changes of EVs from the same number of cells, EVs were isolated from 
normalized volumes of supernatants based on the protein concentrations in the 
whole cell lysates. Cells, nuclei, debris and subcellular organelles were removed 
from the supernatant after serial centrifugation. The EV pellet was collected and 
resuspended for negative staining under transmission electron microscopy (TEM).  
Images of EVs from ten random fields were captured. The numbers of EVs per 
field under TEM was significantly higher in HIV-1-infected macrophages than 
EVs from mock-infected macrophages, suggesting that HIV-1 infection leads to 
increased release of EVs in MDM (Fig. 2.1C-E). Second, EVs isolated from 
infected human macrophages were subjected to Western blots for specific EV 
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markers, including ALG-2 interacting protein (Alix) and flotillin-2. Consistent with 
TEM data, Western blot analysis revealed increased levels of Alix and flotillin-2 in 
EV lysates from HIV-1-infected cells, compared with those from uninfected 
cultures (Fig. 2.1F, G). Western blot also showed intact levels of voltage-
dependent anion channels (VDAC) from whole cell lysates. Absence of VDAC 
from EV lysates was confirmed to exclude contamination of mitochondria in 
isolated EVs (Fig. 2.1H). 
 Similarly, when murine microglia cell line BV2 was treated with 
lipopolysaccharide (LPS) for immune activation, the EV number was significantly 
higher in the LPS-treated EV2 compared with the untreated group (Fig. 2.2A-C). 
The increased release of EVs from LPS-treated EV2 cells was further confirmed 
by Western blot detecting EV markers, Alix and flotillin-2 (Fig. 2.2D, E). Because 
EVs were isolated from normalized volumes of supernatants based on their 
corresponding whole cell protein concentrations, a higher number of EVs in TEM 
and increased immunoreactivities of EV markers in Western blots from HIV-1-
infected macrophages and LPS-stimulated microglia suggest that HIV-1 infection 
and immune activation both increase EV release from the cultures. 
 
EVs mediate GLS1 release in HIV-1-infected MDM and immune-activated 
microglia 
 To determine whether EVs are the main mechanism for GLS1 release in 
HIV-1-infected MDM and immune-activated microglia, we treated the cultures 
with GW4869, a neutral sphingomyelinases (nSMase) inhibitor, for 24 hours prior 
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to EVs isolation. GW4869 is known to disrupt in the biogenesis of EVs by 
inhibiting the generation of ceramide [134, 171]. Because GW4869 was 
dissolved in DMSO, we used DMSO as a solvent control for GW4869 and used 
the same amount of DMSO in each dose of the GW4869 treatment. EV markers, 
Alix and flotillin-2, were both increased in the EVs isolated from HIV-1-infected 
MDM (Fig. 2.3A-C). Pretreatment with GW4869 for 24 hours reduced the levels 
of Alix and flotillin-2 in the EVs isolated from HIV-1-infected MDM, indicating the 
increased EV release in HIV-1-infected MDM could be blocked by GW4869 (Fig. 
2.3A-C). The protein levels of GAC, a GLS1 isoform previously identified to have 
neurotoxic potential, were also increased in EVs after HIV-1 infection and 
diminished after GW4869 treatment, indicating that EVs carried GAC as cargo 
and that HIV-1 increases GAC release through EVs (Fig. 2.3A, D). Supernatants 
were collected from the mock-infected, HIV-1-infected with or without GW4869 
and subjected to RT activity assay. The results indicated that after seven days of 
HIV-1 infection, the treatment of GW4869 with different concentration did not 
affection the HIV-1 virus replication, indicating GW4869 is inhibiting the release 
of EV through a mechanism other than lowering HIV-1 infection (Fig. 2.3E). 
 Consistent with HIV-1 infection, LPS activation of microglia line BV2 cells 
also lead to increased EV secretion (Fig. 2.4A-C). After treatment with increasing 
concentrations of GW4869, the increase of Alix and Flotillin-2 in the EVs isolated 
from LPS-activated microglia was blocked, suggesting that immune activation 
also increases EV release in microglia (Fig. 2.4A-C). Importantly, GAC protein 
levels were also increased in EVs after LPS activation and diminished after 
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GW4869 treatment, confirming that immune activation also increases GAC 
release through EVs (Fig. 2.4A, D). 
 
EVs isolated from HIV-1-infected MDM and immune-activated microglia 
mediate extracellular glutamate production through GLS1 
 The identification of EVs in mediating GAC release raises the question of 
the functional relevance of GAC to EVs. HIV-1 infection is known to increase 
extracellular levels of glutamate in human macrophages [71]. We treated cell-free 
HIV-1-infected supernatants with 5 mM glutamine, the reaction substrate for 
GLS1 enzyme, in the presence of 6-Diazo-5-oxo-L-norleucine (L-DON), a GLS 
inhibitor. The levels of glutamate production, as determined by RT-HPLC, 
increased after HIV-1 infection, which was dependent on glutamine (Fig. 2.5A). 
Furthermore, the elevation of glutamate was blocked by L-DON, indicating that 
the released GLS1 promotes glutamate generation in the extracellular fluid of 
HIV-1-infected MDM (Fig. 2.5A). More importantly, EV pellets extracted from both 
mock- and HIV-1-infected MDM were directly tested for GLS1 activity by HPLC. 
EVs were incubated with neurobasal media with or without glutamine for two 
days. Interestingly, the levels of glutamate generated in EVs from HIV-1-infected 
cultures elevated significantly compared with mock-infected control (Fig. 2.5B). 
Low-speed pellets were collected after 10,000 g centrifugation, which may 
contain subcellular organelles and debris. Interestingly, blockage of GLS1 activity 
by L-DON was only observed in the EVs but not in the low-speed pellets from 
HIV-1-infected MDM, suggesting that EVs are the specific compartments for 
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GLS1 release and responsible for excess glutamate production (Fig. 2.5B). To 
further investigate how EVs facilitate glutamine hydrolysis through the GLS1, we 
determined the level of vesicular glutamate transporter (VGLUT) in the EV 
lysates from HIV-1 infected MDM through Western blots (Fig. 2.5C, D). VGLUT 
levels increased after HIV-1 infection and decreased after GW4869 treatment, 
consistent with the overall EV levels. These results indicate VGLUT is a 
component of EVs and suggest that glutamate transporters on the EV lipid 
bilayer may facilitate the transportation of glutamate. Consistent with HIV-1-
infected MDM, EVs isolated from the supernatant of LPS-stimulated microglia 
significantly increased glutamate generation, which could be blocked by L-DON 
(Fig. 2.6A). Taken together, these data suggest that GLS1 released through EVs 
in HIV-1-infected MDM and immune-activated microglia maintains enzyme 
activity and promotes glutamate generation.  
 
GLS1-containing EVs induce neurotoxicity  
 To investigate the functional significance of GLS1-containing EVs from 
HIV-1-infected MDM and immune-activated microglia, EVs were collected and re-
suspended in the neuronal culture medium. The volumes of culture medium used 
to re-suspend EVs were adjusted based on the whole cell protein concentration 
in the same culture. Rat cortical neurons (RCN) treated with 1 µl, 10 µl or 100 µl 
per well of EVs from mock-infected MDM didn’t show significant neurotoxicity 
(Fig. 2.7A, B). However EVs extracted from HIV-1-infected MDM had significantly 
lower viabilities (Fig. 2.7C) and higher neurotoxicity (Fig. 2.7E) compared with 
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those treated with EVs from mock-infected cells. However, the EV-induced 
toxicity was rescued at the presence of BPTES, a GLS1 inhibitor, when 100 µl of 
EVs were incubated with RCN (Fig. 2.7D, F). When RCN was treated with 100 
ng/ml of soluble receptor for TNF, the toxicity induced by EVs from HIV-1-
infected MDM was not rescued, which suggests the toxicity is not affected 
through TNF-α (Fig. 2.7G). Interestingly, the toxicity was rescued by the 
application of MK801, an uncompetitive agonist of N-Methyl-D-Aspartate (NMDA) 
receptor, indicating the toxicity of GLS1-containing EVs was through the 
excitotoxicity via glutamate (Fig. 2.7H). 
 Similarly, EVs from control BV2 cells didn’t show any neurotoxicity (Fig. 
2.8A), but neurotoxicity was observed in neurons treated with EVs isolated from 
LPS-activated microglia in a volume-dependent manner (Fig. 2.8B). This toxicity 
was blocked by BPTES (Fig. 2.8C). Interestingly, RCN didn’t demonstrate toxicity 
when treated with EV free supernatants collected after EV isolation (Fig. 2.8D), 
indicating the toxicity was majorly induced via EVs. These data suggest that the 
GLS1-containing EVs induce neurotoxicity through the GLS1 activity in the EVs. 
 
HIV-1-infected MDM induce neurotoxicity through GLS1-containing EVs 
 To determine whether HIV-1-infected MDM induce neurotoxicity through 
GLS1-containing EVs, we obtained supernatants from HIV-1-infected 
macrophages that were pre-treated with 2, 5 or 10 µM of GW4869 and used the 
supernatants to treat RCN for neurotoxicity. Similar to prior experiments, we used 
DMSO as a solvent control for GW4869 and used the same amount of DMSO in 
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each dose of the GW4869 treatment. Neurotoxicity was determined through 
quantifications of neuronal antigen MAP2 with either MAP2 ELISA (Fig. 2.9A) or 
MAP2 immunostaining (Fig. 2.9B-H). The HIV-1-infected MDM-induced 
neurotoxicity was blocked by increasing concentrations of GW4869 (Fig. 2.9), 
indicating that supernatants from HIV-1-infected MDM induce neurotoxicity 
through EVs. Next, we isolated EVs from mock-infected and HIV-1-infected MDM 
and investigated the direct neurotoxicity of EVs. Interestingly, EVs isolated from 
HIV-1-infected MDM manifested higher levels of neurotoxicity as determined by 
MAP2 ELISA (Fig. 2.10A) or MAP2 immunostaining (Fig. 2.10C-I), when 
compared with EVs from mock-infected control. However, the EV-free 
supernatants did not show any toxicity from the indication of MAP2 ELISA (Fig. 
2.10B). Treatment of GW4869 prior to EV isolation rescued EV-induced 
neurotoxicity at a dose dependent manner, suggesting a direct neurotoxic role of 
EVs from HIV-1-infected MDM. Together, these data strongly suggest that HIV-1-
infected macrophages induce neurotoxicity through EVs. 
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2.5 Discussion 
 Our previous reports have described the release of GLS1 into extracellular 
space during neuroinflammation or HIV-1 infection. However, key molecular 
mechanisms that regulate GLS1 release remain unknown. Our current study 
presents two important new findings regarding the GLS1 release. First, EVs 
contain GLS1, which is a key enzyme for generating glutamate in the brain, and 
GLS1 is released into the extracellular fluid primarily via EVs in HIV-1-infected 
cells and immune-activated microglia. Second, HIV-1 infection and LPS 
activation increase the magnitude of EV release from macrophages and 
microglia. Interestingly, increased release of GLS1-containing EVs also induces 
excitotoxicity in RCN. The toxic effect of EVs was reversed by glutaminase 
inhibitors and EV inhibitors. These observations suggest that EVs may contribute 
to excess glutamate production in macrophages in the context of HIV-1 
neurotoxicity. 
The physiological relevance of this observation is significant, where 
elevated endogenous levels of GLS1 have been reported in the post-mortem 
brain tissues of HIV-1-associated dementia patients [53, 113]. Furthermore, it 
has been demonstrated that both of the upregulated GLS1 isoforms, KGA and 
GAC, are released from the inner membrane of mitochondria into the cytosol 
through the permeability transition pore [72, 111]. However, it is the extracellular 
glutamate that causes neurotoxicity, and the mechanisms by which cytosolic 
GLS1 is released into the cell supernatant have not been previously established. 
The current study provides strong evidence that GLS1-containing EVs are the 
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main mechanism for the release of GLS1 from the macrophage and microglia 
cytosol into the extracellular compartment, where the extracellular glutamate 
subsequently induces neurotoxicity. It is unclear how GLS1 hydrolyzes 
extracellular glutamine inside EVs. We have detected vesicular glutamate 
transporter in the EV lysates from HIV-1 infected MDM (Fig. 2.5), suggesting that 
EVs may transport glutamate across its lipid bilayer through glutamate 
transporters. 
Our studies were designed to rigorously establish the purity and 
characterization of the isolated microvesicles. To confirm complete separation of 
EVs from mitochondria, the absence of the mitochondrial marker protein voltage-
dependent anion-selective channel (VDAC) and cytochrome C was confirmed 
through Western blots. Secondly, to characterize the EVs, both scanning and 
transmission electron microscopies were used, which showed vesicles ranging in 
size from 50 nm to 500 nm. Western blot could not detect the presence of GLS1 
in exosomes collected from commercially available exosome kits, suggesting that 
GLS1 is selectively packed into the larger form of EVs rather than into smaller 
exosomes. Furthermore, because the EV-free supernatants and the pellets that 
contained cellular debris had minimum GLS1 activities and GLS1 was found 
predominantly in the isolated EVs fraction, we concluded that EVs are the 
primary instigator in facilitating GLS1 release in HIV-1-infected macrophages and 
LPS-activated microglia.  
Chronic activation of the immune system is a hallmark of progressive HIV 
infection yet its etiology remains obscure. Circulating microbial products such as 
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LPS, possibly derived from the gastrointestinal tract, was significantly increased 
in chronically HIV-infected individuals and may be a cause of HIV-related 
systemic immune activation [172]. In our report, when LPS was used to treat BV2 
microglia cell line, high levels of GLS1 were found in the supernatants leading to 
neurotoxicity. These results support the pathogenic effect of the immune 
activation in the CNS during HIV-1 infection. The discovery that GLS1 
upregulation induces GLS1 release via EVs may have a broader implication to 
other neurological diseases, where excitotoxicity and GLS1 are involved. 
Because EVs are abundantly expressed in the CNS, it is tempting to speculate 
whether qualitative or quantitative changes of EVs contribute more broadly to 
neurological diseases. In addition, the regulation of EVs could be exploited as a 
novel therapeutic target. 
In the current study, we also utilized an EV inhibitor, GW4869, to block the 
release of the EVs. Both GLS1 and EV markers were decreased in a dose-
dependent manner by GW4869, suggesting that GLS1 release is through EVs. 
GW4869 is an inhibitor for nSMase2, which is responsible for the production of 
ceramide. Ceramide has been found enriched in EVs and involved in the 
formation of vesicles. Our results point to a possible mechanism of EVs release 
in the microglia and macrophages through the endosomal sorting complex 
required for transport (ESCRT) machinery or a ceramide-dependent pathway 
[134, 171]. These interesting possibilities remain the subject of future 
investigation. Furthermore, we have demonstrated that the neurotoxicity by HIV-
1-infected MDM was abolished by pre-treatment with GW4869, which indicates 
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that GLS1-containing EVs are the neurotoxic factors in HIV-1-infected 
macrophages and immune-activated microglia. Therefore, inhibiting the release 
of EVs might become a potential therapeutic approach for the treatment of HAND 
patients.  
 Three aspects of the studies merit further investigation. First, how is 
cytosolic GLS1 loaded into EVs for extracellular secretion from macrophages? 
Second, how are GLS1-containing EVs formed? Third, what mediates the 
release of GLS1-containing EVs from the plasma membrane? Autophagosomes, 
inflammasomes or mitochondria-derived vesicles may provide possible 
mechanisms for these events to occur. It is possible that HIV-1 infection and 
immune activation of macrophages and microglia directly lead to the release of 
GLS1-containing EVs, however, other possibilities also need to be explored.  
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2.6 Conclusion 
 In summary, our studies address important questions regarding the 
cellular mechanisms of GLS1 release, implicating a critical role of EVs. This 
newfound knowledge of neurotoxic GLS1-containing EVs has potentially 
important clinical implications for neurologic diseases such as HAND. Developing 
inhibitors of EV formation and release or inhibitors of GLS1 might yield effective 
new therapies for reducing glutamate-induced neurotoxicity in HIV-1-infected and 
immune-activated individuals.  
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2.7 Figures 
Figure 2.1 
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Figure 2.1 HIV-1 infection increases EVs release from macrophages.  
 (A) MDM was fixed at 7th day post HIV-1 infection and subsequently subjected 
to SEM for EV detection. Magnification, 6000 X.  (B) High-magnification image of 
the corresponding small box area in panel A was shown. Magnification, 24000 X. 
(C-E) eVs were isolated through differential centrifugation from normalized 
volumes of cultural supernatants and observed under TEM using negative 
staining. Representative TEM images of EVs from mock-infected MDM (C), HIV-
1 infected MDM (D) were shown. (E) EVs numbers in C and D were quantified by 
manually counting from a total of 10 random vision fields. Results are 
representative of TEM images and quantification results are means ± SD of EV 
numbers from 10 fields of TEM images. ** denotes p < 0.01 in comparison to 
controls. (F) EVs were isolated from normalized volumes of supernatants in 
mock-infected and HIV-1-infected MDM cultures. The levels of Alix and flotillin-2 
in EVs were determined by Western blot. (G) Densitometric quantifications of the 
Alix and flotillin-2 protein levels were presented as fold change relative to the 
untreated controls. (H) The level of mitochondrial marker, voltage-dependent 
anion channels (VDAC) was detected in both whole cell and EV lysates to 
exclude contamination in EVs.  
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Figure 2.2 
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Figure 2.2 Immune activation increases EVs release from microglia.  
 (A-B) EVs were isolated through differential centrifugation from normalized 
volumes of cultural supernatants and observed under TEM using negative 
staining. Representative TEM images of EVs from untreated microglia (A), and 
LPS-stimulated microglia (B) were shown. (C) EVs numbers in C, D and E, F 
were quantified by manually counting from a total of 10 random vision fields. 
Results are representative of TEM images and quantification results are means ± 
SD of EV numbers from 10 fields of TEM images. ** denotes p < 0.01 in 
comparison to controls. (D) EVs were isolated from normalized volumes of 
supernatants in untreated and LPS-stimulated microglia cultures. The levels of 
Alix and flotillin-2 in EVs were determined by Western blot. (E) Densitometric 
quantifications of the Alix and flotillin-2 protein levels were presented as fold 
change relative to the untreated controls. 
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Figure 2.3 
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Figure 2.3 EVs mediate GLS1 release in HIV-1-infected MDM. 
(A) At 7 days post-infection, mock-infected and HIV-1 infected MDM were treated 
with GW4869 for 24 hours in serum-free media. EVs were isolated from the 
supernatants and EV protein lysates were prepared. The levels of Alix, flotillin-2, 
and GAC were determined by Western blots. (B-D) Densitometric quantifications 
of the Alix (B), flotillin-2 (C), and GAC (D) protein levels were presented as fold 
change relative to the mock-infected controls. (E) Supernatants were collected 
and subjected to RT activity assay. DMSO was used as solvent control for 
GW4869. Western blot results shown are representative of three independent 
experiments. Quantification results shown are means ± SD of experiments 
performed in triplicate (n = 3 donors). ** and *** denotes p < 0.01 and 0.001 in 
comparison to mock-infected or untreated control; #, ## and ### denote p < 0.05, 
0.01 and 0.001 in comparison to HIV-infected or immune-activated groups, 
respectively. 
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Figure 2.4 
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Figure 2.4 EVs mediate GLS1 release in immune-activated microglia. 
 (A) EVs were isolated from the supernatants of control and LPS-treated 
microglia in the presence and absence of GW4869. EV lysates were subjected to 
Alix, flotillin-2, and GAC detection through Western blots. Results shown are 
representative of three independent experiments. (B, C, D) Densitometric 
quantifications of the Alix (B), flotillin-2 (C), and GAC (D) protein levels were 
presented as fold change relative to the untreated controls. DMSO was used as 
solvent control for GW4869. Western blot results shown are representative of 
three independent experiments. Quantification results shown are means ± SD of 
experiments performed in triplicate (n = 3 donors). ** and *** denotes p < 0.01 
and 0.001 in comparison to mock-infected or untreated control; #, ## and ### 
denote p < 0.05, 0.01 and 0.001 in comparison to HIV-infected or immune-
activated groups, respectively. 
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Figure 2.5 
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Figure 2.5. EVs isolated from HIV-1-infected MDM mediate extracellular 
glutamate production through GLS1. 
(A) Cell-free supernatants from mock-infected and HIV-1-infected macrophages 
were incubated with or without glutamine and 1 mM L-DON ex vivo for two days. 
The resulting glutamate levels were determined by RP-HPLC. *** denotes p < 
0.001 in comparison to the 5 mM glutamine group in HIV-1-infected samples. (B) 
EVs were isolated from cell-free supernatants from mock-infected and HIV-1-
infected MDM and incubated with or without glutamine and 1 mM L-DON ex vivo 
for two days. Glutamate generation in EVs or low speed (LS) pellets was 
determined by RP-HPLC. Low-speed pellets were collected after 10,000 g 
centrifugation, which contained subcellular organelles and debris. (C) At 7 days 
post-infection, mock-infected and HIV-1 infected MDM were treated with 
GW4869 for 24 hours in serum-free media. EVs were isolated from the 
supernatants and EV protein lysates were prepared. The levels of vGluT were 
determined by Western blots. (E) Densitometric quantifications of vGluT protein 
levels were presented as fold change relative to the mock-infected controls. 
Western blot results shown are representative of three independent experiments. 
Quantification results shown are means ± SD of experiments performed in 
triplicate (n = 3 donors). *** denotes p < 0.001 in comparison to 5 mM glutamine 
group in HIV-1-infected samples or mock-infected control; ### denotes p < 0.001 
in comparison to HIV-infected. 
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Figure 2.6 
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Figure 2.6 EVs isolated from immune-activated microglia mediate 
extracellular glutamate production through GLS1. 
(A) EVs were isolated from cell-free supernatants from untreated and LPS-
activated microglia and incubated with or without glutamine and 1 mM L-DON ex 
vivo for two days. Glutamate generation in EVs was determined by RP-HPLC. *** 
denotes p < 0.001 in comparison to 5 mM glutamine group in LPS-activated 
samples. Results are means ± SD of triplicate samples and are representative of 
three independent experiments. *** denotes p < 0.001 in comparison to 5 mM 
glutamine group in LPS-treated samples. 
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Figure 2.7 
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Fig 2.7. GLS1-containing EVs from HIV-1-infected MDM induce 
neurotoxicity. 
EVs were isolated from both mock-infected and HIV-1-infected MDM at 7 days 
post-infection. EVs were resuspended in neuron medium. Different volume of 0, 
1, 10 and 100 µl of EVs from mock-infected (A, B) and HIV-1-infected (C) MDM 
were added to the RCN and incubated for 24 hours. 100 µl of EVs from mock-
infected and HIV-1-infected MDM were added in RCN with or without 10 µM of 
BPTES, a GLS1 inhibitor, neutralizing TNF-α antibody or MK801 for 24 hours (C, 
F, G, H). Neurotoxic potentials of EVs were determined by MTT (C, D) and MAP2 
ELISA assays (E, F). *, ** and *** denote p < 0.05, 0.01 and 0.001 in comparison 
to controls, respectively; #, ## and ### denote p < 0.05, 0.01 and 0.001 in 
comparison to HIV-infected group, respectively. Results are expressed as means 
± SD of triplicate samples and are representative of three independent 
experiments. 
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Figure 2.8 
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Fig 2.8. GLS1-containing EVs from immune activated microglia induce 
neurotoxicity. 
(A-D) EVs were isolated from BV2 microglia cells treated with LPS overnight. 
EVs were resuspended in neuron medium. Different volume of 0, 1, 10 and 100 
µl of EVs from control BV2 cells without LPS treatment (A) and LPS-treated (B) 
BV2 were added to the RCN and incubated for 24 hours. 100 µl of EVs were 
added in RCN with or without 10 µM of BPTES, a GLS1 inhibitor, for 24 hours (C). 
EV free supernatants after differential centrifugation were also collected and 100 
µl of supernatants were added to RCN with or without 10 µM of BPTES for 24 
hours. Neurotoxic potentials of EVs were determined by MTT (A, B, D) and 
MAP2 ELISA assays (C). * and *** denote p < 0.05 and 0.001 in comparison to 
controls, respectively; ### denotes p < 0.001 in comparison to LPS-treated group, 
respectively. Results are expressed as means ± SD of triplicate samples and are 
representative of three independent experiments. 
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Figure 2.9 
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Fig 2.9. HIV-1-infected macrophages induce neurotoxicity through GLS1-
containing EVs. 
At 7 days post-infection, mock-infected and HIV-1 infected macrophages were 
treated with GW4869 at different dosages for 24 hours. Cell-free supernatants 
and EVs were collected and added to RCN cultures for neurotoxicity. DMSO was 
used as solvent control for GW4869. (A, B) Neurotoxic potentials of the 
supernatants were determined by MAP2 ELISA assay (A) and quantification of 
MAP2 fluorescence in immunostaining (B). (C-H) Neurotoxic potentials of 
supernatants with EVs were determined by MAP2 immunostaining followed by 
quantification of the intensity of MAP2 fluorescence after EVs treatment (B). * 
and *** denote p < 0.05 and 0.001 in comparison to mock-treated control, 
respectively ; ## and ### denote p < 0.01 and 0.001 in comparison to DMSO-
pretreated HIV-infected group, respectively. Results are expressed as means ± 
SD of triplicate samples and are representative of three independent experiments. 
Results are representative of 20 fluorescent images from three independent 
experiments. 
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Figure 2.10 
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Figure 2.10. HIV-1-infected macrophages induce neurotoxicity through 
GLS1-containing EVs. 
At 7 days post-infection, mock-infected and HIV-1 infected macrophages were 
treated with GW4869 at different dosages for 24 hours. Cell-free supernatants 
and EVs were collected and added to RCN cultures for neurotoxicity. DMSO was 
used as solvent control for GW4869. (A, B) Neurotoxic potentials of EV (A) and 
EV free supernatants (B) were determined by MAP2 ELISA assay. (C-I) 
Neurotoxic potentials of EVs were determined MAP2 immunostaining (C-H) 
followed by quantification of the intensity of MAP2 fluorescence after EVs 
treatment (I). * and *** denote p < 0.05 and 0.001 in comparison to mock-treated 
control, respectively ; ## and ### denote p < 0.01 and 0.001 in comparison to 
DMSO-pretreated HIV-infected group, respectively. Results are expressed as 
means ± SD of triplicate samples and are representative of three independent 
experiments. Results are representative of 20 fluorescent images from three 
independent experiments. 
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Chapter 3 
GLS1 are involved in the release of extracellular vesicles in activated 
macrophages and microglia 
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Abstract 
 Extracellular vesicles (EVs) are important in the intercellular 
communication in the central nervous system. Their release is increased during 
neuroinflammation and neurological disorders. Our previous data demonstrated 
an increased release of EVs from HIV-1-infected macrophages, and that these 
EVs have neurotoxic effects. However, the mechanism of elevation of EV release 
in those HIV-1-infected cells remains unknown. In our current study, we 
investigated glutaminase 1 (GLS1), which is a mitochondrial enzyme critical for 
glutamine metabolism.  GLS1 is upregulated in HIV-1-infected macrophages and 
microglia. We propose that HIV-1 infection increases GLS1, leading to a 
metabolic status that favors the EVs generation and release. This new 
understanding of the metabolic control of EV release in HIV-1-infected cells will 
shed light on HIV-1 pathobiology and neurological complications.  
 Cultures of human primary microglia and monocyte-derived macrophages 
culture system and macrophage-tropic HIV-1ADA were used to study the 
regulation of EVs during HIV-1 infection. EVs were isolated through differential 
centrifugations. A gene overexpression system, delivered via adenovirus vector, 
was utilized to overexpress GLS1 in the cell culture to mimic the upregulation of 
GLS1 during HIV-1 infection. A brain-specific GLS1 transgenic mouse line was 
created to model GLS1 elevation in vivo. BPTES was used to specifically inhibit 
GLS1 activity. Transmission electron microscopy and Western blot were used to 
quantify the EVs released from cells and brain tissues. Glutamate and glutamine 
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levels were determined by reverse phase high-performance liquid 
chromatography.  
 An elevated number of EVs was found in the supernatants of HIV-1-
infected macrophages and microglia when compared with controls. 
Overexpression of GLS1 in macrophages and microglia cultures lead to 
increased release of EVs. Conversely, blocking the GLS1 activity by BPTES 
significantly reduced EV release and glutamate generation in HIV-1-infected 
macrophages and microglia, suggesting a critical role of GLS1 in EV release. 
Interestingly, we detected an elevated release of EVs in the brain tissues of 
GLS1 transgenic mice, suggesting that GLS1 is also important for EV release in 
vivo.  
 GLS1 is essential for EVs release in HIV-1-infected macrophages and 
microglia. Therefore, blocking EV release through GLS1 inhibitors may serve as 
a novel therapeutic strategy against the HIV-1 pathobiology and neurological 
complications. 
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3.1 Introduction 
 Glutaminase 1 (GLS1) is a metabolic enzyme located on the inner 
membrane of mitochondria, which deaminases glutamine into glutamate.  GLS1 
is known to be associated with cancer cell research and CNS disease [53, 173, 
174]. GLS1 is the predominant glutamine-utilizing enzyme in the CNS, where 
GLS2 is expressed at a lower level [175].  
 In the past decade, our lab has focused on understanding the role of 
GLS1 in the brain using molecular and chemical tools. We have reported that 
GLS1 plays a role in microglia and macrophages and later in neurons during 
brain inflammation and injury [53, 112]. During HIV-1 infection and immune 
activation, glutamate level is excessively increased due to the upregulation of 
GLS1 [53, 72, 112, 149]. The elevated glutamate levels have been associated 
with the neuronal injury and excitotoxicity in various CNS disorders [102, 176, 
177]. Interestingly, the upregulation of GAC in the postmortem brain tissue of 
HAND patients was identified [53, 112]. Recently, we also reported that 
extracellular vesicles (EVs) contain GLS1 from HIV-1infected macrophages and 
immune-activated microglia. We also reported that these EVs induce toxicity in 
neurons [178]. 
 EVs are secretary vesicles derived from either cell membranes or 
multivesicular bodies that range from 50 nm up to 500 nm. In physiological 
conditions, EVs facilitate the cell-to-cell interactions between neurons and glial 
cells through the transfer of the neurotransmitter cargos. EVs have lipid bilayers, 
which protect their cargos from degradation via proteases and RNases [135, 155, 
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160]. However, in response to stress, such as DNA damage, hypoxia, exposure 
to viruses or bacteria, the release of EVs increases and the contents within the 
EVs alter as well. As EVs can be detected in a variety of biological fluids such as 
plasma and cerebral spinal fluid (CSF), they are prime candidates for biomarkers 
of diseases [167].  
 EVs have been detected at an elevated level in the cerebral spinal fluid in 
patients with mild to severe AD, PD, prion disease and ALS [163, 179]. More 
importantly, protein markers of EVs are present in neuritic plaques in AD brains. 
This evidence suggests that EVs play a potential role in the pathogenesis of 
neurodegenerative diseases and neuroinflammation. Moreover, the defective 
metabolism of sphingolipids in the brain has been associated with EV release. 
Studies have reported that sphingolipids are increased in different regions of AD 
brains and may promote Aβ biogenesis [180]. Studies have shown that the 
neutral sphingomyelinase (nSMase) inhibitor, GW4869 significantly reduces the 
release of EVs and its neurotoxicity in HAND and AD [178, 180]. However, upon 
all evidence, it remains unclear what the mechanism of EV regulation is.  
 Aside from in vitro models, our lab has developed a new mouse line to 
overexpress GAC in the mouse brain to mimic the pathogenesis during HAND, 
which is competitive with the other available murine models for HAND, including 
HIV-1 glycoprotein 120 (gp120) transgenic mouse, the HIV-1 encephalitic (HIVE) 
mouse, HIV-Tat transgenic mouse and the humanized mouse [181], [182-184]. 
However, none of these HAND models was able to demonstrate the role of GLS1 
in the pathogenesis of HAND. The successful generation of the GAC-
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overexpressing mice demonstrates an increase of brain inflammation, neuronal 
damage and learning and memory deficits. This mouse model also provides a 
strong in vivo tool to study the role of GLS1 in EV regulation. 
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3.2 Materials and Methods 
Culture, HIV-1 and LPS infection of macrophages and microglia 
Human peripheral blood-derived mononuclear cells were isolated through 
leukopheresis from healthy donors. Human macrophages were differentiated in 
Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma Chemical Co., St. Louis, MO) 
with 10% human serum, 50 µg/ml gentamycin, 10 µg/ml ciprofloxacin (Sigma), 
and 1,000 U/ml recombinant human macrophage colony-stimulating factor 
(MCSF) for 7 days. Human fetal microglial cells were obtained from fetal brain 
tissue-derived microglia-astrocytes mixed cultures as previously described [185]. 
The HIV-1ADA strain was used to infect the macrophages and microglia at a 
multiplicity of infection (MOI) of 0.1 and 0.5, respectively. After 24 hours, culture 
medium was changed to remove any remnant virus. Seven days after HIV-1-
infection, culture medium was changed to glutamine-free neurobasal medium for 
24 h and supernatants were collected for subsequent HPLC or Western blot 
analysis. HeLa and BV2 cell lines were obtained from ATCC, and both cell lines 
were grown in DMEM with 10% fetal bovine serum and antibiotics. 
Lipopolysaccharide (LPS) was used to immune activate BV2 cells for 24 h and 
supernatants were collected for HPLC and Western blot analysis. Bis-2-(5-
phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (a generous gift 
presented by Dr. Tsukamoto from John Hopkins and later ordered from Millipore) 
at a concentration of 10 µΜ were added to HIV-1-infected macrophages or LPS-
treated microglia prior to EV isolation. All experiments involving human cell 
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samples are approved by Institutional Review Board of University of Nebraska 
Medical Center. 
 
GAC-overexpressing mice 
 Mouse Gac gene was selected and cloned from a C57 mouse cDNA 
library. The Gac gene was then inserted into the pCAG-Loxp-STOP-Loxp-IRES-
LacZ plasmid at restriction enzyme site Xhol. The plasmid was constructed and 
sequenced specially for forwardly inserted Gac. The linearized plasmid was 
selected and microinjected into the fertilized eggs for the further implantation into 
a pseudopregnant female to create CAG-loxp-GAC mouse in the Mouse 
Genome Engineering Core Facility of UNMC. The stability of the constructed 
plasmid was examined through visualizing the GFP expression in the CAG-lloxp-
GAC mice brains. Four weeks old nestin promoter-driven cre transgenic mice 
(Nestin-Cre mouse) line was purchased from Jackson laboratory (Bar Harbor, 
ME), where the cre activity is only restricted to CNS. The CAG-loxp-GAC mice 
were then mated with Nestin-Cre mice. Nestin-GAC mice were produced and the 
absence of GFP was examined to ensure the success of the generation of GAC-
overexpressing mice. Similarly, Thy-1 promoter-driven cre transgenic mice were 
used to mate with the CAG-loxp-GAC mice to generate Thy-1-GAC mice. DNA 
was extracted from embryonic tissue or adult mouse tail tissue with 
phenol/chloroform. DNA was then purified using isopropanol and ethanol. PCR 
reactions were conducted to genotype all transgenic mice. All mice were housed 
and bred in the Comparative Medicine facilities of the University of Nebraska 
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Medical Center. All procedures were conducted according to protocols approved 
by the Institutional Animal Care and Use Committee of the University of 
Nebraska Medical Center.  
 
Morris Water Maze (MWM) test 
 The training phase and probe phase are the two major parts in MWM test. 
Mice were introduced into a 91 cm circular water tank, which was equally divided 
into four quadrants. Visual cues were placed around the pool to direct mice to the 
submerged 10 cm circular platform. A variety of parameters were recorded to 
evaluate the movement of the mice. For each trial, the mouse was given 60 
seconds to find the submerged platform before guided to the platform. Each 
mouse completed four trials per day during a 5-day training phase. On the 6th day, 
the probe test was conducted. The platform was removed and each mouse was 
given 60 seconds to swim in the tank. The parameters were videotaped and 
analyzed by Ethovision XT (Noldus, Netherlands). 
 
Contextual Fear Conditioning (CFC) test 
 Contextual fear conditioning test was performed following standard 
protocols in the light- and sound-attenuated chambers for mouse (Coulbourn Tru 
Scan Activity Monitoring System for mouse). On the 1st day of the test, mice were 
allowed to habituate in the clean chamber for 300 seconds without any 
stimulation. On the 2nd day, the chamber was scented with 0.1% acetic acid and 
the mice were given two electric shocks at 170 s and 290 s via automated Tru 
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Scan Stimulus. On the 3rd day, the chamber was scented with 0.1% acetic acid 
without shock stimulus. Mice in the chamber were recorded for 180 s. Mouse 
behavior was evaluated under ambient illumination (room light) and was 
recorded by a SAMSUNG digital videocamera above the chamber. The behavior 
recorded was analyzed by Ethovision XT by assessing the time of freezing.  
 
Preparation of adenovirus overexpressing glutaminase 
KGA and GAC were cloned into a Shuttle Vector and Replication-defective 
adenovirus vectors expressing human KGA and GAC were generated by the 
RAPAd® Adenoviral Expression System (Cell Biolabs, Inc. San Diego, CA 92126) 
following the manufacturer’s instruction. Adenoviral constructs were amplified in 
a 293AD cell line (Cell Biolabs, Inc) and purified by ultracentrifugation through a 
CsCl gradient. Quantification of the adenoviral infectious unit was performed 
using Adeno-X™ Rapid Titer Kit (Clontech Laboratories, Inc. Mountain View, CA 
94043). HeLa cells, BV2 cells, or primary human microglia were infected at a 
multiplicity of infection of 50. Cells were used for experiments 2 days after 
infection. 
 
Isolation of EVs from cells  
EVs were isolated from the supernatants of GLS1-overexpressing cells, 
HIV-1-infected macrophages and LPS-activated microglia through differential 
centrifugations. Briefly, the supernatants were first centrifuged at 300 X g for 10 
min to remove free cells, at 3,000 X g for 20 min to remove cellular debris and 
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then 10,000 X g for 30 min to remove free organelles. Lastly, EVs were collected 
by ultracentrifugation at 100,000 X g for 2 h at 4°C. To prepare EVs for Western 
blotting, the EV pellets were lysed in M-PER mammalian protein extraction 
reagent (Thermo Scientific, Pittsburgh, PA). For negative staining, EVs were 
fixed in 2% glutaraldehyde and 2% paraformaldehyde. For glutaminase activity 
assay and neurotoxicity, the EVs were resuspended in 1 ml of glutamine-free 
neurobasal medium.  
 
Isolation of MVs from mice brain 
 EV isolations from the brains were carried out as described previously with 
modifications according to the protocol [186]. Fresh and previously frozen mice 
hemibrains were harvested and dissected finely. Brain samples were then 
treated with 20 units/ml papain (Worthington) in Hibernate E solution (BrainBits, 
Springfield, IL) for 15 minutes at 37 °C. The same volume of cold Hibernate E 
solution was added to the brains samples to stop the reaction of papain. The 
brain tissue was then gently homogenized and filtered through a 40-µm mesh 
filter (BD Biosciences), followed by a centrifugation at 300 X g for 10 min and, 
3000 X g for 20 min at 4 °C to get rid of cells, membranes and debris. After the 
supernatants were filtered through 0.45 µm filter (Thermo Scientific), they were 
subjected to 10, 000 X g for 30 min at 4 °C to eliminate organelles 
contaminations. The supernatants were further centrifuged at 100, 000 X g for 70 
min at 4 °C to pellet EVs. The pellets were then resuspended in filtered PBS, or 
MPER lysate solution for Nanosight or Western blot.  All the samples were 
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ultracentrifuged in ultraclear polycarbonate tubes (Beckman Coulter) that have a 
volume of 13.2 ml. A Beckman Coulter ultracentrifuge (Beckman Coulter 
OptimaL-90K ultracentrifuge; Beckman Coulter, Fullerton, CA, USA) was used 
with a rotor type 41 wi. 
 
Negative staining and electron microscopy 
 EVs were fixed and then spread on the silicon monoxide and nitro-cellular 
film coated copper grid. The droplets were removed with filter paper, air-dried at 
room temperature and then subjected to transmission electron microscopy (TEM). 
For scanning electron microscope (SEM), cells were fixed in 2% glutaraldehyde 
and 2% paraformaldehyde and point dried, mounted and coated with 
gold/palladium.  
 
Nano-particle tracking analysis 
NanoSight NS 300 (Malvern) equipped with an sCMOS camera was utilized to 
analyze the size distribution and concentration of EVs. NanoSight utilizes 
Nanoparticle Tracking Analysis (NTA), which is a combination of light scattering 
and Brownian motion to measure the concentration and size distribution of 
particles in the EV supernatants. After the whole process of EV isolation, the 
pellets were first resuspended in 100 µl of filtered PBS and then diluted by 100 
times. The conditions of the measurements include a temperature of 25 °C, 
viscosity of 1 cP, 25 seconds per capture frame and a measurement time of 60 s. 
All the conditions were kept the same among all the samples. The results 
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indicate the mean sizes and concentration of at least three individual 
measurements. 
 
Toxicity/MTT/MTS assays 
 GLS1 inhibitors were added to HIV-1-infected macrophage or LPS-
activated microglia cultures and cell viability was assessed by MTT assays in 24-
well or 96-well plates.  MTT (Sigma) was added to the cultures to a final 
concentration of 125 µg/ml. The plates were incubated for 30 minutes at 37 °C 
with 5% CO2 and the medium was aspirated. The insoluble formazan was 
solubilized in DMSO, and the concentrations were determined by optical density 
at 490 nm with an ELX808 densitometer (Bio-Tek Instruments, Winooski, and 
VT). Alternatively, Celltiter aqueous one solution cell proliferation assay, which 
contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) was 
utilized to assess cell viability according to the manufacturer instruction. Briefly, 
20 µl of reagent was added into a 100 µl of culture medium, and then incubated 
the plates in a humidified, 5% CO2 and 37 °C atmosphere for 1 hour. The 
absorbance was determined at 490 nm. 
 
Western blot 
 Protein concentrations were determined by Bradford protein assay. SDS 
PAGE separated proteins from whole cell and EVs lysates. After 
electrophoretically transferred to polyvinyldifluoridene membranes (Millipore, 
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Billerica, MA and Bio-Rad, Hercules, CA).  Membranes were incubated overnight 
at 4 °C with polyclonal antibodies for KGA and GAC (Dr.N.Curthoys, Colorado 
State University, Fort Collins, CO), tissue transglutaminase (tTG) (Lab 
Vision/Thermo, Fremont, CA), flotillin-2 (Cell Signaling Technology, Danvers, MA) 
and β-actin (Sigma-Aldrich, St. Louis, MO), followed by horseradish peroxidase-
linked secondary anti-rabbit or anti-mouse secondary antibodies (Cell signaling 
Technology). Antigen-antibody complexes were visualized by Pierce ECL 
Western Blotting Substrate. For quantification of the data, films were scanned 
with a CanonScan 9950F scanner and images were analyzed using the public 
domain NIH image program (developed at the U.S. National Institutes of Health 
and available on the internet at http://rsb.info.nih.gov/nih-image/). 
 
Glutaminase activity assay 
 Highly concentrated whole cell lysates were collected from flasks and 
subjected to GLS activity assay using a two-step assay [187, 188]. Briefly, 
protein concentrations in the lysates were tested by using BCA Protein Assay Kit 
(Pierce). All samples were normalized to same concentration. In the first step, 
fifty milligrams of protein was added to 100 µL of initial assay mix. The mix 
contains 50 mM glutamine, 0.15 M phosphate, 0.2 mM EDTA, and 50 mM tris-
acetate. The PH value of the mix was adjusted to 8.6 and incubated at 37 °C for 
30 min. 10 µL of 3 N hydrochloric acid (HCl) was added to inactivate the 
glutaminase activity and stop the reaction. In the second step, 1 mL of the 
second reaction mix was added, which contained 0.4 mg of purified bovine liver 
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glutamate dehydrogenase (Sigma-Aldrich, St. Louis, MO, USA), 0.08 M Tris-
acetate at pH 9.4, 0.2 M hydrazine, 0.25 mM ADP (adenosine 5'-diphosphate 
sodium salt), and 2 mM NAD (β-nicotinamide adenine dinucleotide hydrate). The 
samples were mixed and incubated for 30 min at room temperature. 100 µL of 
reaction was used for measurement and absorbance was determined at a 
wavelength of 340 nm, glutamate concentration was determined using a 
standard curve of 10, 5, 2.5, 1.25, 0.625, and 0.0 mM glutamate, along with 
negative controls. 
 
Analysis of extracellular glutamate and glutamine by RP-HPLC 
Glutamate levels were analyzed by RP-HPLC using an Agilent 1200 liquid 
chromatograph and fluorescence detector as previously described [14] with a few 
modifications. The experiments utilized 4.6 × 75 mm, 3.5 µm ZORBAX Eclipse 
AAA analytical columns (Agilent). A gradient elution program was optimized for 
glutamate measurement with a flow rate 0.75 ml/min.  
 
Analyses of intracellular glutamate concentrations 
 The intracellular glutamate levels in whole brain lysates of mice and whole 
cell lysates were determined by Amplex Red Glutamic acid/Glutamate Oxidase 
Assay Kit (Invitrogen) based on the manufacturer’s instruction. Brain tissue 
lysates and whole cell lysates were diluted to the same protein concentration 
before the assay. 
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Statistical analysis 
Data are expressed as means ± SD unless otherwise specified. Statistical 
analysis was performed using one way ANOVA, followed by the Tukey-post-test 
for paired observations or two way ANOVA using Bonferroni post-tests to 
compare replicate means. Significance was determined by a p value < 0.05. All 
experiments were performed with cells from at least three donors to account for 
any donor-specific differences. Assays were performed at least three times in 
triplicate or quadruplicate within each assay. 
  
  79 
3.3 Results 
GLS1 overexpression increases EVs release in vitro. 
The molecular mechanism(s) for EV release in HIV-1-infected 
macrophages remain unclear. Our previous reports showed that GLS1 was 
upregulated and caused increased glutamate production in HIV-1-infected 
macrophages [112]. To further study the mechanism of GLS1 and EV release, 
we constructed adenovirus vectors that overexpressed KGA or GAC to mimic the 
upregulation of these isoforms during HIV-1 infection. The extracellular levels of 
glutamate increased significantly in both KGA- and GAC-overexpressing HeLa 
cells at the multiplicities of infection (MOI) of 200 compared with uninfected or 
vector-treated cells (Fig. 3.1A). An MOI of 200 was then used for the following 
GLS1-overexpression experiments. The overexpression of KGA and GAC were 
confirmed by Western blot (Fig. 3.1B). GLS1 enzyme activity assay confirmed 
increased KGA and GAC activity in concentrated protein lysates from KGA- and 
GAC-overexpressing HeLa cells, suggesting that the overexpressed KGA and 
GAC were functional (Fig. 3.1C). Furthermore, protein lysates were utilized to 
test the intracellular glutamate. The level of glutamate was increased after KGA- 
and GAC-overexpression compared with GFP and control group (Fig. 3.1D). 
Consistently, supernatants were collected from each group and cell debris was 
removed. Samples were subjected to RP-HPLC after acid and base treatment to 
determine the extracellular level of glutamate. Both KGA and GAC 
overexpression showed increased glutamate in the supernatants (Fig. 3.1E). 
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Next, we looked at GLS1 activities in the extracellular fluid of the KGA- 
and GAC-overexpressing HeLa cells. Previously, we reported that GLS1 was 
released from the inner membrane of mitochondria in the cytosol in HIV-1-
infected macrophages [111]. However, whether elevation of GLS1 levels induces 
GLS1 translocation or release remains unclear till we proved that GLS1 activity 
was previously detected in the EVs [178]. Consistently, using KGA and GAC 
overexpression, cell-free supernatants showed increased glutamate production 
after addition of glutamine. Furthermore, GLS1 inhibitor, L-DON, blocked the 
excess generation of glutamate in the overexpression supernatants, indicating 
that GLS1 activity was present in the extracellular supernatants from KGA- and 
GAC-overexpressing HeLa cells (Fig. 3.2A). To confirm that glutaminase is 
released from cytosol to extracellular space via EVs in GLS1 overexpression, 
EVs were collected from cell-free supernatants and tested for glutaminase 
activity. EVs that were isolated from KGA- or GAC-overexpressing HeLa cells 
generated significantly higher levels of GLS1 when incubated with glutamine (Fig. 
3.2B). When L-DON was added to the enzyme reactions, the generation of 
glutamate was blocked, suggesting that KGA- and GAC-overexpression induced 
EVs release that contain high levels of GLS1 activities (Fig. 3.2B). Due to the 
limited protein extracted from EVs, extracellular glutamate level was measured 
using RP-HPLC to test the levels of GLS1 activities instead of the traditional 
GLS1 activity enzyme assay. Furthermore, proteins from EVs showed increasing 
EV markers, tTG and flotillin-2 in KGA- and GAC-overexpressing HeLa cells with 
elevated expression of KGA and GAC in the lysates of MVs (Fig. 3.2C-E). 
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However, the level of EV markers in the whole cell lysates did not change (Fig. 
3.2C-E). Together, these data suggest that elevation of GLS1 is sufficient to 
induce the extracellular release of GLS1-containing EVs. 
 
Inhibition of GLS1 activity reduces EVs release in HeLa cells. 
 When treated with EGF, HeLa cells release more EVs to the extracellular 
fluid [189]. Moreover, EGF has been reported to increase the activity of GLS1.  
Therefore, the increase of GLS1 activity by EGF triggers the EVs from HeLa cells 
indicated that the alteration of GLS1 could be a potential mechanism of EVs 
release. To investigate the effect of the GLS1 inhibitors on GLS1 level in whole 
cells, and to further explore the impact of GLS1 inhibitor on EV release, both 10 
µM BPTES, 30 µM carbenoxolone (CBX) or 100 µM L-DON were treated 24 hr 
prior to EV isolation. EVs were collected through differential centrifugation and 
lysed for Western blot. To compare the amount of EV released, the concentration 
of whole cell lysates was measure to normalize to the volume of EVs according 
to the concentration of whole cells. The level of EV markers, flotillin-2 and CD9, 
were decreased under Western blot, indicating a potential inhibition of EV 
release by the GLS1 inhibitors compared with the endogenous levels of GLS1 in 
HeLa cells (Fig. 3.3 E-G). This evidence suggests that blocking GLS1 
significantly reduces the release of EVs in HeLa cells. 
 
Inhibition of GLS1 activity reduces EV release in HIV-1-infected 
macrophages and immune-activated microglia. 
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  In HIV-1-infected macrophages or immune-activated microglia, GLS1 
expression is upregulated and EV release is increased [178]. To further 
investigate whether GLS1 inhibitor can affect the level of EV release in 
macrophages, human macrophages were infected with HIV-1 virus with 10 µM 
BPTES prior to harvest or 5 µM Atazanavir (AZT) on the second day of infection. 
Whole cell lysates were collected to detect the expression level of the GLS1 
isoform, GAC. The treatment of AZT, which inhibits the HIV-1 viral replication, 
significantly decreased the level of GAC that was upregulated during HIV-1 
infection. The addition of BPTES in HIV-1-infected macrophages didn’t reduce 
the protein level of GAC (Fig 3.4A, B). Interestingly, when BPTES was added 
one day after HIV-1 infection, or one day prior to EV isolation, EV lysates showed 
a decreased level of EV markers, Flotillin-2 and tTG from HIV-1-infected 
macrophages. However, when BPTES was added immediately after the HIV-1 
infection, the result of EV release was not affected, indicating BPTES affect the 
EV release in a short-term manner (Fig 3.4C-F).  
 To test the effect of GLS1 inhibitors on microglia, we used a murine 
microglial cell line, BV2 and human microglia cells. When GLS1 inhibitors, 10 µM 
BPTES, or 10 µM CB839 were added to BV2 cells 4 hours prior to LPS treatment 
for overnight, GLS1 inhibitors did not reduce cell viability (Fig. 3.5A). The results 
from GLS enzyme activity assay showed an increased GLS activity in the LPS-
activated BV2 cells but a decreased GLS activity with the treatment of BPTES 
and CB839 (Fig 3.5B). The inhibition of the GLS activity in LPS-stimulated BV2 
cells is stronger in the group treated with CB839 than the group treated with 
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BPTES. Both whole cell lysates and EV lysates were collected and subjected to 
Western blot. The ratio of GAC to β−actin showed no significant change. 
However, EV markers in the EV lysates showed an increase trend after LPS 
treatment and a decrease trend after the treatment of BPTES and CB839 (Fig 
3.5C-G). When the EVs were isolated, PBS priorly filtered through 0.22 µm 
PVDF filter was used to resuspend EV pellets and 10 µl EV was added to 990 µl 
PBS. One hundred times diluted EVs were then subjected to nanoparticle 
tracking analysis. LPS treatment group showed an increased EV particle 
concentration from BV2 cells. Interestingly, the treatment of BPTES and CB839 
both reduce the EV concentrations, which is consistent to the results in Western 
blot (Fig 3.5B). 
 To further verify this effect in human microglia, EVs were isolated from 
LPS-treated human microglia with or without BPTES. Both EV markers, Flotillin-2 
and CD9 showed an increased level of EV release after LPS treatment but a 
decrease after 10 µM BPTES treatment (Fig 3.6A-C).  
 Consistently, these results indicated that GLS1 inhibitors block the release 
of EVs in HIV-1-infected macrophages and LPS-treated microglia. 
 
Brain-specific GLS1 overexpression increases EVs release in vivo. 
 To further investigate the release of EVs in vivo, Nestin-GAC and wild type 
(WT) were generated by crossing Nestin-Cre mice and CAG-loxp-GAC mice and 
PCR reactions were performed to confirm the genotypes of the mice (Fig. 3.7A). 
To first confirm the changes in behaviors that are related to the learning and 
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memory functions, Nestin-GAC mice of 8 weeks old and control littermates were 
first subjected to Morris-Water-Maze (MWM) test and Cued-Contextual Fear 
Conditioning (CFC) test. During MWM test, Nestin-GAC mice tended to spend 
more time and travel a longer distance to reach the target platform and the speed 
of swimming didn’t change compared with WT control from training phase to 
probe test. Overall, the Nestin-GAC mice had fewer crossings over the platform 
area when the platform was removed on the probe test day than WT control (Fig 
3.7B). Interestingly, in the CFC test, Nestin-GAC mice showed less freezing in 
the percentage compared with WT control on the probe test day (Fig 3.7C). 
These results indicate that Nestin-GAC mice have impaired learning and memory 
related to hippocampal and cortical functions. After the behavioral tests, groups 
of mice were sacrificed, half of the brain of each mouse was subjected to EV 
isolation, and the other half was lysed to extract total proteins. The proteins from 
the kidney of both Nestin-GAC mice and the WT control mice were also collected 
as controls. The protein levels of GAC in the brain from Nestin-GAC mice were 
significantly higher than that from control littermates (Fig 3.7D, E). Intracellular 
glutamate levels were higher in Nestin-GAC brain lysates but the same in the 
kidney, indicating GAC overexpression is only limited to the mouse brain (Fig 
3.7F). Furthermore, proteins were extracted from different regions of the brains of 
Nestin-GAC mice and WT control. The levels of intracellular glutamate were 
consistently higher in the hippocampus, cortex, midbrain and cerebellum (Fig 
3.7G). Altogether, these results confirmed the GAC overexpression in the Nestin-
  85 
GAC mouse brain and demonstrated significant learning and memory deficits 
that are similar to the HAND model. 
 EVs were isolated and purified from hemibrains of both WT and Nestin-
GAC mice through the specifically developed/modified protocol [186]. The 
expression levels of EV markers, Alix and Flotillin-2 were both increased using 
Western blot from Nestin-GAC mice compared with WT mice (Fig. 3.8A-C). 
Similarly, EVs extracted from Thy1-GAC mice, which is another breed of GAC 
overexpressing mouse model, were also increased compared with WT control 
using negative staining by TEM (Fig.3.8D-F). Excitingly, these data indicate that 
the brain-specific GAC overexpression increases EVs release in vivo. 
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3.5 Discussion 
 Chronic neuroinflammation is a hallmark in the pathogenesis of 
neurodegenerative diseases including HAND, Alzheimer’s disease, Parkinson’s 
disease, multiple sclerosis and amyotrophic lateral sclerosis [48, 49, 51, 86]. HIV-
infected or immune activated macrophages and microglia play a pivotal role in 
brain inflammation and neuronal injury through the release of various soluble 
neurotoxic factors including glutamate [49, 71, 74, 78, 190].  
 We have previously reported that the upregulation of GLS1 in activated 
macrophages and microglia significantly induce neurotoxicity through the excess 
production of glutamate [53, 72, 112]. It is also reported that the mitochondrial 
GLS1 was translocated from the inner membrane of mitochondria to the cytosol 
upon the oxidative stress induced by HIV-infection or immune activation. 
Furthermore, the release of GLS1 from cytosol to extracellular milieu was proven 
to be dependent on EVs, which induce excitotoxicity in neurons [178]. However, 
a remaining key question is how the EVs are formed, released and regulated. 
The study in this chapter presents two major findings regarding EV release. First, 
the upregulation of GLS1 induces increasing release of EVs in HIV-1-infected 
and immune-activated macrophages and microglia. Second, the increasing 
release of EVs in GAC-overexpressing mice is associated with the learning 
impairment and neuronal injury. These observations suggest that GLS1 could be 
a key component in the regulation of EV release, which could be essential in the 
mechanism study of EVs. 
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 The pathogenic role of GLS1 in neurodegeneration has been closely 
associated with clinical implications. Dysregulation of GLS1 has been reported 
not only in the pathogenesis of HAND, but also in cancer proliferation and 
metastasis. The increasing release of GLS1 could be crucial in causing the 
prolonged brain inflammation, increased neuronal injury and worsening disease 
progression in HAND. GLS1 is a key enzyme in the glutamine metabolism, where 
glutamate is produced and functions in glutamate signaling and synaptic 
plasticity [191-195]. The dysregulation of GLS1 causing the aberrant release of 
glutamate is strongly associated with the memory loss and learning deficits due 
to disrupted functioning of NMDA receptors [194-196]. The impaired glutamate 
transporter in the neighboring astrocytes to take up extra glutamate during HIV-1 
infection further emphasizes the essential pathogenic role of GLS1 [87, 88]. 
Taken together, the neurotoxic role of GLS1-containing EVs raised more 
attention to the study. 
 To further study the role of GLS1, a new adenovirus was constructed to 
overexpress both GLS1 isoforms to mimic the upregulation of GLS1 during HIV-1 
infection or immune activation. Both KGA- and GAC- overexpressing HeLa cells 
displayed significantly increased GLS1 enzyme activity. Together with the 
increasing levels of intracellular and extracellular glutamate, the GLS1 
overexpression in vitro was proven successfully. Due to low protein concentration 
and low yield of EVs, it is difficult to conduct GLS enzyme activity assay. Instead, 
EVs were collected from GLN-free supernatants and incubated with or without 
GLN or GLS1 inhibitor. The glutamate level is measured by RP-HPLC, which can 
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also provide the indication of GLS1 activity in the EVs. GLS1 activity was 
detected in both the supernatants and EVs portions from the KGA- and GAC- 
overexpressing HeLa cells. Furthermore, an increasing level of EV markers, tTG 
and flotillin-2 were detected using Western blot. The absence of mitochondrial 
markers, cytochrome c, VDAC, GM130, PMP70, and Calreticulin exclude the 
contamination of mitochondria, Golgi, peroxisomes, and ER in the EVs after 
isolation. Interestingly, when HeLa cells were treated with GLS1 inhibitor, BPTES, 
CBX and CB839, the release of EVs were significantly reduced. Similar results 
were also observed in the HIV-1-infected macrophages and LPS-treated 
microglia when GLS1 inhibitors were added. That release of EVs was reversed 
by the GLS1 inhibitors suggests that the level of GLS1 regulates the release of 
EVs. 
 Aside from the evidence in vitro, we also generated a novel mouse model 
to overexpress GAC in vivo, which demonstrated upregulated GLS1 and 
elevated glutamate in the whole brain, hippocampus, cortex, midbrain, and 
cerebellum. The mice also displayed increased reactive astrogliosis, 
neuroinflammation and learning and memory deficits. We also found that the 
release of EVs is consistently increased in two GAC-overexpressing models, 
Nestin-GAC and Thy1-GAC mice. However, it needs to be further investigated 
whether GLS1 inhibitors can block the EV release in vivo and whether the 
blocking of EVs in GAC-overexpressing can attenuate the elevated 
neuroinflammation and neuronal injury. 
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 Further investigation is needed to elucidate the mechanism of how GLS1 
is regulating the EVs. It is also unclear whether the level of GLS1 in the EVs 
affects the regulation of EV release. By inhibiting GLS1 activity, CBX has been a 
newly discovered GLS1 inhibitor that can reduce the release of EVs (manuscript 
in preparation). Because the GLS1 is important in the glutamine metabolism and 
EVs have been reported to be associated with sphingolipids, including ceramide, 
it is possible that GLS1 is regulating the EV release through both metabolisms 
and their connection in this regulation. 
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3.6 Conclusion 
 In summary, the studies in this chapter address the importance of GLS1 in 
the regulation of EVs, which implicate a crucial role of GLS1. Our new 
understanding of how GLS1 regulates the release of EVs in vitro and in vivo has 
a potential clinical implication in neurologic diseases such as HAND and 
neuroinflammation and also cancer research. The effective inhibition of EV 
release using GLS1 inhibitors sheds lights on developing potential therapeutic 
targets in GLS1-EVs related diseases. 
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3.7 Tables and Figures 
Figure 3.1 
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Figure 3.1. Both KGA and GAC are successfully overexpressed by 
adenovirus in vitro. 
(A) Cell-free supernatants were collected from adenovirus-infected HeLa cell 
cultures at the MOI of 10, 50 and 200. RP-HPLC were used to determine the 
extracellular glutamate level. (B) GLS1 was overexpressed through adenovirus 
vectors that express KGA and GAC isoforms in HeLa cells at a multiplicity of 
infection (MOI) of 200. Two days after adenovirus infection, proteins lysates were 
collected from whole cells and the levels of KGA, GAC, tTG and flotillin-2 were 
determined by Western blot. Actin was used as loading control. (C) Protein 
lysates were collected from KGA- and GAC-overexpressing HeLa cells at the 
MOI 200. GLS1 activities were determined by the enzyme activity assay. GFP 
adenovirus Ad-GFP was used as vector control. (D, E) Extracellular and 
intracellular glutamate levels from adenovirus-KGA and -GAC infected HeLa cells 
with MOI 200 were detected by Amplex Red Glutamic acid/Glutamate oxidase 
Assay Kit and RT-HPLC, respectively. Quantification results shown are means ± 
SD of experiments performed in triplicate (n = 3 donors). *** and **** denotes p < 
0.001and 0.0001, compared with the Ad-GFP group. 
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Figure 3.2 
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Figure 3.2. KGA and GAC overexpression increase EV release in vitro.  
(A) Cell-free supernatants from control (CTL), Ad-GFP, Ad-KGA and Ad-GAC 
infected HeLa cells were incubated with or without 5 mM glutamine (Gln) and 1 
mM L-DON ex vivo for two days. The glutamate levels were determined by RP-
HPLC. (B) EVs were isolated from cell-free supernatants from four different 
groups of HeLa cells and incubated with or without 5 mM glutamine (Gln) and 1 
mM L-DON ex vivo for two days. Glutamate production from EVs was determined 
by RP-HPLC. (C) Protein lysates were prepared from the whole cell lysates and 
EVs pellets. The levels of EVs markers, tTG and flotillin-2 were analyzed by 
Western blot. EVs protein loading was normalized with protein concentrations in 
whole cell lysates. Mitochondrial marker, cytochrome c, was used as a control to 
exclude contamination of EV pellets. (D, E) Densitometric quantifications of the 
protein levels in EVs were presented as fold change relative to that in control EV 
lysate. The protein levels in whole cell lysates were presented as fold change 
relative to β-actin in whole cells. Western blot results shown are representative of 
three independent experiments. Quantification results shown are means ± SD of 
experiments performed in triplicate (n = 3 donors). *, ** and *** denotes p < 0.05, 
0.01 and 0.001, compared with the Ad-GFP group. 
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Figure 3.3.  
 
  
  96 
Figure 3.3. Inhibition of glutamine metabolism reduces EVs release in vitro.  
(A) Hela cells were treated with BPTES and L-DON for 24 hours. Protein lysates 
were prepared from the EVs pellets in control and GLS1 inhibitor-treated Hela 
cells. The levels of EVs markers, flotillin-2 and CD9 were analyzed by Western 
blot. EVs protein loading was normalized with protein concentrations in whole cell 
lysates. (B, C) Densitometric quantifications of the protein Levels were presented 
as fold change relative to that in control EV lysate. Western blot results shown 
are representative of three independent experiments. Quantification results 
shown are means ± SD of experiments performed in triplicate (n = 3 donors).   *, 
** and *** denotes p < 0.05, 0.01 and 0.001, compared with that of the control 
Hela cells.  
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Figure 3.4 
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Figure 3.4. Inhibition of glutamine metabolism reduces EVs release in HIV-
1-infected macrophages. Mock-infected or HIV-1-infected macrophages were 
treated with 10 µM BPTES 24 h prior to harvest or treated with 10 µM AZT.  (A) 
Whole cell lysates were collected and GAC was measured using Western blot. 
(B) Densitometric quantification of the protein level of GAC in whole cell lysates 
was presented as fold change relative to β−actin. (C) EVs were isolated from 
mock-infected or HIV-1-infected macrophages treated with 10 µM BPTES at the 
day after infection or one day prior to EV isolation. EVs protein loading was 
normalized with protein concentrations in whole cell lysates. EV markers, Alix, 
flotillin-2, and tTG were measured using Western blot. (D-F) Densitometric 
quantifications of the protein levels of in EV markers were presented as fold 
change relative to that in mock-infected control EV lysates. Western blot results 
shown are representative of three independent experiments. Quantification 
results shown are means ± SD of experiments performed in triplicate (n = 3 
donors).  *, ** and *** denotes p < 0.05, 0.01 and 0.001, compared with that of 
the control microglia cells. # and ### denotes p < 0.05 and 0.001 compared with 
that of the HIV-1-infected macrohphages. 
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Figure 3.5  
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Figure 3.5. Inhibition of glutamine metabolism reduces EVs release in 
immune-activated microglia. 
BV2 cells were treated with 10 µM BPTES or 10 µM CB839 4 hours prior to LPS 
treatment overnight. BV2 cell regular medium was changed to serum-free DMEM 
medium when GLS1 inhibitors were added. (A) Cell viability was measured after 
overnight treatment using MTS assay. (B) Protein lysates were collected from 
LPS-treated BV2 cells with or without GLS1 inhibitors. GLS1 activities were 
determined by the enzyme activity assay. (C, D) Protein lysates were prepared 
from whole cell and EV pellets in control, LPS-treated and LPS-treated with 
GLS1 inhibitor BV2 cells. The levels of GAC in whole cells, EVs markers, Alix 
and flotillin-2 in EVs were analyzed by Western blot. EVs protein loading was 
normalized with protein concentrations in whole cell lysates. PMP70, LAMP-1, 
and VDAC were also measured in the whole cell and EV lysates to exclude 
contaminations. (E-G) Densitometric quantification of the protein level of GAC in 
whole cell lysates was presented as fold change relative to β−actin. 
Densitometric quantifications of the protein levels of in EV markers were 
presented as fold change relative to that in control EV lysates. (H) Quantifications 
of the NanoSight NTA of vesicle concentration for samples from control, LPS-
treated, LPS-treated with BPTES and LPS-treated with CB839 groups. Western 
blot results shown are representative of three independent experiments. 
Quantification results shown are means ± SD of experiments performed in 
triplicate (n = 3 donors).  * and ** denotes p < 0.05 and 0.01, compared with that 
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of the control BV2 cells. # denotes p < 0.05 compared with that of the LPS-
treated BV2 cells.   
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Figure 3.6 
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Figure 3.6. Inhibition of glutamine metabolism reduces EVs release in 
immune activated human microglia.  
(A) Human microglia were treated with or without 10 µM BPTES 4 h prior to LPS 
activation. Microglia media was changed to serum-free DMEM medium when 
BPTES were added. EVs were isolated and normalized depending on whole cell 
concentrations. EV markers, flotillin-2 and CD9 were measured using Western 
blot. (B, C) Densitometric quantifications of the protein levels of in EV markers 
were presented as fold change relative to that in mock-infected control EV 
lysates. Western blot results shown are representative of three independent 
experiments. Quantification results shown are means ± SD of experiments 
performed in triplicate (n = 3 donors).  *, ** and *** denotes p < 0.05, 0.01 and 
0.001, compared with that of the control microglia cells. # and ### denotes p < 
0.05 and 0.001 compared with that of the LPS-treated microglia cells. 
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Figure 3.7 
 
  
  105 
Figure 3.7. GAC overexpression is confirmed in Nestin-GAC mouse. 
(A) The scheme shows the generation of Nestin-GAC transgenic mouse to 
specifically overexpress GAC in the CNS. A plasmid vector was engineered to 
overexpress GAC and then was microinjected into the fertilized egg. The egg 
was implanted in the uterus of a pseudopregnant female to create CAG-loxp-
GAC mouse. CAG-loxp-GAC mice were mated with Nestin-Cre mice to produce 
Nestin-GAC mice. (B) Morris-Water-Maze test was performed to determine the 
spatial learning and memory of Nestin-GAC mice. After 5 days of the training 
phase, the probe test was conducted on the 6th day. Nestin-GAC mice spent 
significantly less time in the target quadrant and had fewer crossings of the target 
place. (C) The Cued-Fear-Conditioning test was used to examine the memory of 
Nestin-GAC mice. (D) Protein lysates were prepared from whole brains and the 
expression levels of GAC were determined by Western blot. (E) Densitometric 
quantifications of the protein Levels were normalized to β-actin and presented as 
fold change relative to that in wild-type whole brain lysates. (F) Tissue glutamate 
levels were determined using the Amplex Red Glutamic acid/Glutamate Oxidase 
Assay Kit. (G) Protein lysates from different regions of mice brain were prepared 
and the expression levels of GAC were determined by Western blot. 
Quantification data were normalized to β-actin and presented as fold change in 
WT mice. Data are shown as the means ± SD. * and ** denote p < 0.05 and 0.01 
compared with WT mice, N = 4 for Nestin-GAC and WT mice. 
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Figure 3.8 
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Figure 3.8. Brain-specific GLS1 overexpression increases EVs release in 
vivo. 
(A) Wild-type and Nestin-GAC mice were sacrificed at 12-16 weeks old. Brains 
were removed, and for each brain, the right hemibrain was processed for EVs 
isolation and the left hemibrain was homogenized for brain lysates. Protein 
lysates were prepared from the EVs pellets in wild type and Nestin-GAC 
hemibrains. The levels of EVs markers, tTG and flotillin-2 in the EVs lysates were 
analyzed by Western blot. EVs protein loading was normalized with the weight of 
their corresponding hemibrains before the EVs isolation. (B, C) Densitometric 
quantifications of the protein Levels were presented as fold changes relative to 
that in wild-type EV lysate. (D-F) Brain tissues from adult Thy1-GAC mice were 
dissected and EVs were isolated using the same techniques described above. 
EVs collected from WT (D) and Thy1-GAC (E) were evaluated via negative 
staining under TEM. Images shown were representative of each group. EVs 
numbers per vision fields (N = 10) were quantified. *** denotes p < 0.001 
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Chapter 4 
Potential mechanism of GLS1 in the regulation of extracellular vesicles in 
macrophages and microglia 
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4.1 Abstract 
 Extracellular vesicles (EVs) are important in the intercellular 
communication in the central nervous system and their release is increased upon 
neuroinflammation and neurological disorders. Our previous data demonstrated 
an increased release of EVs from HIV-1-infected macrophages and immune-
activated microglia that is neurotoxic. It also showed this release can be blocked 
by the inhibition of ceramide production. However, the mechanism of increasing 
EV release during HIV-1-infected and immune activation remains unknown. In 
the current study, we investigated glutaminase 1 (GLS1), a mitochondrial 
enzyme critical for glutamine metabolism, in EV release in HIV-1-infected 
macrophages and immune-activated microglia. We propose that HIV-1 infection 
increases GLS1, leading to a metabolic status that favors EV generation and 
releases through the glutamine and lipid metabolism. This new understanding of 
metabolic control of EV release in HIV-1-infected macrophages and immune-
activated microglia will shed light on HIV-1 pathobiology and neurological 
complications.  
  Human primary monocyte-derived macrophages and murine microglia 
BV2 cell culture system and macrophage-tropic HIV-1ADA and lipopolysaccharide 
(LPS) were used to study the regulation of EVs during HIV-1 infection and 
immune activation. EVs were isolated through differential centrifugations. GLS1 
inhibitors, BPTES, and CB839 were used to specifically inhibit GLS1 activity. 
Ceramide and alpha-ketoglutarate were added after the treatment of GLS1 
inhibitors to study the change of EV release. Transmission electron microscopy, 
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Nano-particle tracking analysis and Western blot were used to quantify the EVs 
released from cells. Glutamate and glutamine levels were determined by reverse 
phase high-performance liquid chromatography.  
  An elevated number of EVs was found in the supernatants of HIV-1-
infected macrophages and immune-activated microglia when compared with 
controls. Conversely, blocking the GLS1 activity by BPTES, CB839 and CBX 
significantly reduced EV release and glutamate generation in HIV-1-infected 
macrophages and immune-activated microglia, suggesting a critical role of GLS1 
in EV release. Consistently, the addition of glutamine substrate increases EV 
release during HIV-1 infection or immune activation. Interestingly, the inhibited 
EV release was reversed by the addition of ceramide and alpha-ketoglutarate. 
Identifying these two factors as critical downstream effectors for GLS1 inhibitors.  
 In conclusion, these findings support GLS1 as an essential enzyme that 
regulates through key metabolic intermediate ceramide and α-ketoglutarate 
during HIV-1-infection and immune activation. Therefore, blocking EV release 
through GLS1 inhibitors may serve as a novel therapeutic strategy to block the 
adverse effect of EVs during HIV-1 pathobiology and neurological complications. 
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4.2 Introduction 
 EVs have drawn attention by their facilitation of the interactions between 
neurons and glial cells via their transfer of cargos. EVs are also been significantly 
altered in response to stress and inflammation. EVs have been reported to be 
associated with neurodegenerative diseases such as Alzheimer’s disease, 
Parkinson disease, amyotrophic lateral sclerosis, prion disease and HIV-1-
associated neurocognitive disorders (HAND). The detection of EVs in various 
biological fluids such as plasma and cerebral spinal fluid (CSF) provides a 
potential role for EVs as biomarkers of diseases, including neurological disorders 
[171, 179, 197-200]. EVs have been detected at an elevated level in the cerebral 
spinal fluid in patients with mild to severe AD [167]. More importantly, protein 
markers of EVs are present in neuritic plaques in AD brains [167, 201, 202]. Our 
study also provided evidence of the increasing release of EVs in HAND models 
[178]. However, the regulation of EVs formation and release needs to be further 
elucidated. 
 GLS1 is a metabolic enzyme that is known to be associated with cancer 
cell proliferation and transformation [173, 174]. GLS1 is also essential in the 
glutaminolysis pathway, where it provides an energy source to the proliferating 
cells and acts as a nitrogen substrate for lipid and protein synthesis [203-205]. 
During glutaminolysis, glutamine is catalyzed into glutamate and its subsequently 
intermediate, α-ketoglutarate, which then enters the TCA cycle [110, 206, 207]. 
Glutamine serves as a nitrogen donor to protein glycosylation via the 
hexosamine pathway [208, 209], and as a source for the production of 
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glutathione in the resistance pathway against oxidative stress [205]. Furthermore, 
glutamine metabolism has also been identified to be important in various CNS 
diseases, including ALS, MS, and HAND [178, 210, 211]. Our recent reports 
suggest that GLS1 is upregulated and responsible for the increasing release of 
glutamate through elevated glutamine metabolism [72, 112]. More interestingly, 
in our current study, we found that GLS1 is positively regulating the release EVs. 
However, the mechanism of how GLS1 increases EV release remains unclear. 
Furthermore, the role of glutamine metabolism in EV release remains 
understudied. 
  Recent studies indicate that the formation and secretion of EVs are 
largely dependent on the proper function of ceramide, which is a type of 
sphingolipids catalyzed by neutral sphingomyelinase (nSMase) from 
sphingomyelin. The defective metabolism of sphingolipids in the brain has also 
been reported to be associated EVs with AD, where increasing EV release is 
reported as a crucial contributor to the toxicity of amyloid beta and tau 
phosphorylation [180]. The EV release is also reversed by the inhibition of the 
nSMase pathway [212, 213]. Studies show that the nSMase inhibitor, GW4869 
significantly reduces the release of EVs and its neurotoxicity in HIV-infected or 
immune-activated macrophages and microglia and in AD model in vitro and in 
vivo, indicating the potential involvement of ceramide in the EV biogenesis [178, 
180, 214]. However, the correlation between GLS1, glutamine metabolism, 
ceramide and EV hasn’t been investigated. Therefore, in this chapter, we will 
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explore the possibilities and discuss the potential mechanism of GLS1 regulation 
of EV release in response to the glutamine and sphingolipid metabolisms.  
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4.3 Materials and Methods 
Culture, HIV-1 and LPS infection of macrophages and microglia 
Human peripheral blood-derived mononuclear cells were isolated through 
leukopheresis from healthy donors. Human macrophages were differentiated in 
Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma Chemical Co., St. Louis, MO) 
with 10% human serum, 50 µg/ml gentamycin, 10 µg/ml ciprofloxacin (Sigma), 
and 1,000 U/ml recombinant human macrophage colony-stimulating factor 
(MCSF) for 7 days. Human fetal microglial cells were obtained from fetal brain 
tissue-derived microglia-astrocytes mixed cultures as previously described [185]. 
The HIV-1ADA strain was used to infect the macrophages and microglia at a 
multiplicity of infection (MOI) of 0.1 and 0.5, respectively. After 24 hours, the 
culture medium was changed to remove any remnant virus. Seven days after 
HIV-1-infection, the culture medium was changed to glutamine-free neurobasal 
medium for 24 h and supernatants were collected for subsequent HPLC or 
Western blot analysis. HeLa and BV2 cell lines were obtained from ATCC, and 
both cell lines were grown in DMEM with 10% fetal bovine serum and antibiotics. 
Lipopolysaccharide (LPS) was used to immune activate BV2 cells for 24 h and 
supernatants were collected for HPLC and Western blot analysis. Bis-2-(5-
phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (a generous gift 
presented by Dr. Tsukamoto from John Hopkins and later ordered from Millipore) 
at a concentration of 10 µΜ was added to HIV-1-infected macrophages or LPS-
treated microglia prior to EV isolation. All experiments involving human cell 
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samples are approved by Institutional Review Board of University of Nebraska 
Medical Center. 
 
Isolation of EVs from cells  
EVs were isolated from the supernatants of GLS1-overexpressing cells, 
HIV-1-infected macrophages and LPS-activated microglia through differential 
centrifugations. Briefly, the supernatants were first centrifuged at 300 X g for 10 
min to remove free cells, at 3,000 X g for 20 min to remove cellular debris and 
then 10,000 X g for 30 min to remove free organelles. Lastly, EVs were collected 
by ultracentrifugation at 100,000 X g for 2 h at 4°C. To prepare EVs for Western 
blotting, the EV pellets were lysed in M-PER mammalian protein extraction 
reagent (Thermo Scientific, Pittsburgh, PA). For negative staining, EVs were 
fixed in 2% glutaraldehyde and 2% paraformaldehyde. For glutaminase activity 
assay and neurotoxicity, the EVs were resuspended in 1 ml of glutamine-free 
neurobasal medium.  
 
Negative staining and electron microscopy 
 EVs were fixed and then spread on the silicon monoxide and nitro-cellular 
film coated copper grid. The droplets were removed with filter paper, air-dried at 
room temperature and then subjected to transmission electron microscopy (TEM). 
For scanning electron microscope (SEM), cells were fixed in 2% glutaraldehyde 
and 2% paraformaldehyde and point dried, mounted and coated with 
gold/palladium.  
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Nano-particle tracking analysis 
A NanoSight NS 300 (Malvern) equipped with an sCMOS camera was utilized to 
analyze the size distribution and concentration of EVs. NanoSight utlizes 
Nanoparticle Tracking Analysis (NTA), which is a combination of light scattering 
and Brownian motion technologyto measure the concentration and size  and 
distribution of particles in the EV supernatants. After the whole process of EV 
isolation, the pellets were first resuspended in 100 µl of filtered PBS and then 
diluted by 100 times. The conditions of the measurements include temperature of 
25 °C, viscosity of 1 cP, 25 seconds per capture frame and a measurement time 
of 60 s. All of the conditions were kept the same amongst all of the samples. The 
results indicate the mean sizes and concentration of at least three individual 
measurements. 
 
Toxicity/MTT/MTS assays 
 GLS1 inhibitors were added to HIV-1-infected macrophage or LPS-
activated microglia cultures and cell viability was assessed by MTT assays in 24-
well or 96-well plates.  MTT (Sigma) was added to the cultures for a final 
concentration of 125 µg/ml. The plates were incubated for 30 minutes at 37 °C 
with 5% CO2 and the medium was aspirated. The insoluble formazan was 
solubilized in DMSO, and the concentrations were determined by optical density 
at 490 nm with an ELX808 densitometer (Bio-Tek Instruments, Winooski, and 
VT). Alternatively, Celltiter aqueous one solution cell proliferation assay, which 
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contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) was 
utilized to assess cell viability according to the manufacturer instructions. Briefly, 
20 µl of reagent was added into a 100 µl of culture medium, and then the plates 
were incubated the plates in a humidified, 5% CO2 and 37 °C atmosphere for 1 
hour. The absorbance was determined at 490 nm. 
 
Western blot 
 Protein concentrations were determined by Bradford protein assay. SDS 
PAGE separated proteins from whole cell and EVs lysates. Afterwards they were 
electrophoretically transferred to polyvinyldifluoridene membranes (Millipore, 
Billerica, MA and Bio-Rad, Hercules, CA).  Membranes were incubated overnight 
at 4 °C with polyclonal antibodies for KGA and GAC (Dr.N.Curthoys, Colorado 
State University, Fort Collins, CO), tissue transglutaminase (tTG) (Lab 
Vision/Thermo, Fremont, CA), flotillin-2 (Cell Signaling Technology, Danvers, MA) 
and β-actin (Sigma-Aldrich, St. Louis, MO), followed by horseradish peroxidase-
linked secondary anti-rabbit or anti-mouse secondary antibodies (Cell signaling 
Technology). Antigen-antibody complexes were visualized by Pierce ECL 
Western Blotting Substrate. For quantification of the data, films were scanned 
with a CanonScan 9950F scanner and images were analyzed using the public 
domain NIH image program (developed at the U.S. National Institutes of Health 
and available on the internet at http://rsb.info.nih.gov/nih-image/). 
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Glutaminase activity assay 
 Highly concentrated whole cell lysates were collected from flasks and 
subjected to GLS activity assay using a two-step assay [187, 188]. Briefly, 
protein concentrations in the lysates were tested by using BCA Protein Assay Kit 
(Pierce). All samples were normalized to same concentration. In the first step, 
fifty milligrams of protein was added to 100 µL of initial assay mix. The mix 
contains 50 mM glutamine, 0.15 M phosphate, 0.2 mM EDTA, and 50 mM tris-
acetate. The PH value of the mix was adjusted to 8.6 and incubated at 37 °C for 
30 min. 10 µL of 3 N hydrochloric acid (HCl) was added to inactivate the 
glutaminase activity and stop the reaction. In the second step, 1 mL of the 
second reaction mix was added, which contained 0.4 mg of purified bovine liver 
glutamate dehydrogenase (Sigma-Aldrich, St. Louis, MO, USA), 0.08 M Tris-
acetate at pH 9.4, 0.2 M hydrazine, 0.25 mM ADP (adenosine 5'-diphosphate 
sodium salt), and 2 mM NAD (β-nicotinamide adenine dinucleotide hydrate). The 
samples were mixed and incubated for 30 min at room temperature. 100 µL of 
reaction was used for measurement and absorbance was determined at a 
wavelength of 340 nm, glutamate concentration was determined using a 
standard curve of 10, 5, 2.5, 1.25, 0.625, and 0.0 mM glutamate, along with 
negative controls. 
 
Analysis of glutamate and glutamine by RP-HPLC 
Glutamate levels were analyzed by RP-HPLC using an Agilent 1200 liquid 
chromatograph and fluorescence detector as previously described [14] with a few 
  119 
modifications. The experiments utilized 4.6 × 75 mm, 3.5 µm ZORBAX Eclipse 
AAA analytical columns (Agilent). A gradient elution program was optimized for 
glutamate measurement with a flow rate 0.75 ml/min.  
 
Analyses of glutamate concentrations 
 The intracellular glutamate levels in whole brain lysates of mice and whole 
cell lysates were determined by Amplex Red Glutamic acid/Glutamate Oxidase 
Assay Kit (Invitrogen) based on the manufacturer’s instruction. Brain tissue 
lysates and whole cell lysates were diluted to the same protein concentration 
before the assay. 
 
Statistical analysis 
Data are expressed as means ± SD unless otherwise specified. Statistical 
analysis was performed using ANOVA, followed by the Tukey-post-test for paired 
observations. Significance was determined by a p value < 0.05. All experiments 
were performed with cells from at least three donors to account for any donor-
specific differences. Assays were performed at least three times in triplicate or 
quadruplicate within each assay. 
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4.4 Results 
EV release in HIV-1-infected macrophages is dependent on glutamine. 
 Our previous work has demonstrated the role of GLS1 in the regulation of 
EV release. However, the mechanism of how GLS1 regulates the release 
remains unclear. To further study our hypothesis, different concentrations of 
glutamine were added to HIV-1-infected macrophages one day prior to harvest 
when media was changed into serum free DMEM. Three different concentrations 
were used, including 1 mM, 2 mM and 5 mM. EVs were isolated from the 
supernatants collected from HIV-1-infected macrophages and subjected to 
negative staining. TEM was used to capture images of EVs at magnification of 
2700 X (Fig 4.1A-D) and 42,000 X (Fig 4.1E-H). Seven random fields were 
chosen by the instructor at the TEM core facility lab, who is blinded from the 
experiments and samples identifications. Quantification of EVs showed a 
significant increase of EVs at a concentration of 1 mM and high concentrations of 
glutamine-treated groups remain a high EV release but no significant dose-
dependent effect (Fig 4.1A-I). The extracellular supernatants were then prepared 
for RP-HPLC. Glutamate generation was found to be increased with the 
increasing concentrations of glutamine in the supernatants (Fig 4.2A, B). We 
collected protein lysates from both the whole cells and EVs. The expression level 
of GAC under different concentrations of glutamine did not change compared to 
control group. GAC was also detected in the EVs as previously reported [178]. 
EV markers, Alix, flotillin-2 and CD9 were also detected using Western blot. The 
level of EV markers in the whole cell level is consistent. However, EV markers 
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were higher in HIV-1-infected macrophages with glutamine concentrations of 1 
mM and 2 mM. Surprisingly, the 5 mM treatment group did not show a significant 
increase of EV markers as compared with the control. These results indicate that 
the presence of glutamine is important for the EV release in HIV-1-infected 
macrophages. 
 
EV release in immune-activated microglia is dependent on glutamine. 
 To further investigate whether EV release is dependent on glutamine, BV2 
cells were utilized to study the association of glutamine and the regulation of EV 
release. Different concentrations of glutamine were added six hours prior to LPS 
treatment. The presence of glutamine boosted the survival of BV2 cells, 
indicating the importance of glutamine (Fig 4.3A). The extracellular glutamate is 
increased significantly at the increasing level of glutamine added to the cell 
cultures. Nanoparticle tracking analysis showed that EV release was increased at 
the concentration of 2 mM or 5 mM (Fig 4.3B, C). Furthermore, the Western blot 
of whole cells showed increased GAC levels at 2 mM and 5 mM glutamine 
concentrations (Fig 4.3E, F). The Western blot of EVs showed an increase in the 
EV markers, Alix and flotillin-2, at increased glutamine concentrations (Fig 4.3E, 
G, H). Altogether, these results demonstrated that glutamine is involved in the EV 
release in immune-activated microglia cells. 
 
EV release in immune-activated microglia is associated with the level of α-
ketoglutarate. 
  122 
 Glutamine metabolism is an essential process to generate glutamate and 
thus α−ketoglutarate for energy production. To further study the potential 
pathway of GLS1-associated EV release, 1 mM of α−ketoglutarate (α−KG) was 
added with GLS1 inhibitors. Cell viability did not change upon treatment of GLS1 
inhibitors and α−KG (Fig 4.4A). Whole cells lysates were collected and subjected 
to a GLS1 enzyme activity assay. GLS1 activity increased after LPS treatment 
and decreased after the treatment of GLS1 inhibitors in the presence of 1 mM 
α−KG (Fig 4.4C). EVs were then either isolated and resuspended using filtered 
PBS or lysed for Western blot. EVs were diluted for 100 times and subjected to 
nanoparticle tracking analysis. The decreased EV release after GLS1 inhibitors 
treatment was significantly reversed by the addition of α−KG (Fig 4.4B). 
Furthermore, EV lysates were subjected to Western blot. With the presence of 
α−KG, the level of EV markers, Alix and flotillin-2 were significantly increased 
even with the treatment of GLS1 inhibitors, BPTES or CB839 (Fig 4.4D-F). These 
results suggest that α−KG could be the downstream product of glutamate that is 
associated with the regulation of EV release. 
 
EV release in immune-activated microglia is associated with sphingolipid 
metabolism. 
 Our previous report has shown that the release of EV can be blocked by 
the presence of the nSMase inhibitor, GW4869, which is an inhibitor of the 
production of ceramide [178]. Therefore, we hypothesized that adding ceramide 
to the LPS-treated BV2 with GLS1 inhibitors would help restore the release of 
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EVs. To test this hypothesis, we used two concentrations of ceramide, 50 µM or 
100 µM with or without GLS1 inhibitors. LPS-treatment and GLS1 inhibitors 
treatment with or without ceramide didn’t induce cell loss (Fig 4.5A). 50 µM of 
ceramide was utilized for following experiments. GLS1 activity increased after 
LPS treatment and decreased after the treatment of GLS1 inhibitors in the 
presence of ceramide (Fig 4.5B). Nanoparticle tracking analysis results showed 
that when 10 µM BPTES or CB839 was added, the release of EVs was 
decreased. Interestingly, when ceramide was added, the release of EVs 
increased (Fig 4.5C), indicating that the ceramide pathway of sphingolipid 
metabolism is involved in GLS1 regulated release of EVs.  
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4.5 Discussion 
 Our current study has focused on the identification of key pathogenic 
components for HAND. Our previous studies demonstrated a strong link between 
GLS and the pathogenesis of HAND via the overproduction of glutamate and 
related neuronal damage [49, 53, 71, 72, 108, 188]. Over the years, GLS1 has 
garnered more attention regarding the essential role it plays in normal and 
pathological human physiology. The knockout of GLS1 leads to lethal offspring 
one day after birth in mouse models, which indicates the critical role of GLS1 in 
the early development. We have also reported that GLS1 is essential for the 
proper functioning of neural progenitor cells including neuronal survival together 
with proliferation and differentiation [215]. During neuroinflammation, the 
activation of GLS1 and subsequently upregulated levels of GLS1 are associated 
with HIV-1 infection or immune activation and subsequent neurotoxicity [178].  
 In previous reports, it has been reported that GLS1 is involved in the 
regulation of EV release. However, the exact mechanism remains to be 
elucidated. In this study, we presented three major findings regarding the 
potential mechanism of EV release. First, the release of EVs is dependent on the 
presence of glutamine and its product glutamate. Second, the downstream 
product of glutamate, α−KG, can reverse the inhibition of EV release by GLS1 
inhibitors, indicating that α−KG could be an effector for EV release. Third, the 
inhibition of EV release via GLS1 inhibitors could be mediated by the 
sphingolipid, ceramide pathway, as we have shown the addition of ceramide can 
rescue the reduced EV release. These observations suggest that GLS1 could 
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regulate EV release through the glutamine metabolism and sphingolipid 
metabolism. 
 To investigate our hypotheses on the mechanisms of GLS1’s regulation of 
EV release, we tested the concentrations of isolated EVs from groups including 
glutamine-deprived, or 1 mM, 2 mM and 5 mM of glutamine. A wider range of 
glutamine concentration was utilized in order to study the effects of lower levels 
of glutamine on EV release. When 0.04 mM or 0.2 mM of glutamine was used to 
treat LPS-stimulated BV2 cells, the EV concentrations didn’t show a significant 
increase compared with the control group. Changes in EV release were only 
observed till at a lowest glutamine level of 1 mM. The average sizes of the 
isolated EVs were consistent in all treatment groups, which were above 100 nm 
(data not shown). LPS treatment also did not alter the size of the released EVs. 
However, the increase of glutamine concentration from 1 mM to 5 mM did not 
show a significant or dose-dependent trend of increase of EV release, indicating 
the necessity of glutamine in the culture to release EVs. A potential rationale is 
that glutamine metabolism provides a possible energy resource for the EV 
budding. However, the detailed mechanism needs to be further elucidated. 
 When glutamine is involved in the EV release, the downstream product, α-
KG, which is dependent on glutamine, could be an important regulator for EV 
release. Therefore, after the addition of GLS1 inhibitors, BPTES or CB839, to 
LPS-treated BV2 cells, 1 mM of α-KG was also added to the cultures prior to EV 
isolation. Interestingly, the presence of α-KG rescued the reduced EV release 
after treatment with GLS1 inhibitors. The inhibition of glutamate production from 
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GLS1 inhibitors leads to a reduced generation of α-KG. When α-KG was 
compensated, the level of EV release was rebooted, indicating that the EV 
release could be regulated through glutamine and α-KG. However, further study 
is warranted on whether the addition of α-KG boosts production of glutamate, or 
if this effect is due to the direct actions of α-KG. One possibility is that when α-
KG enters the TCA cycle, energy production is increased. The increase 
production of ATP could activate the increased release of EV via P2X7 receptors, 
which could also be a further action of the mechanism.  
 Previously, we reported using GW4869 could effectively inhibit the release 
of EVs in HIV-1-infected macrophages and LPS-treated microglia [178]. Studies 
have also shown that GW4869 could inhibit EV release in vitro and in vivo in AD 
models and prion diseases [180, 214, 216-220]. It has also been reported that 
sphingolipid metabolism could be involved in EV release in microglia and 
neurological diseases [213, 221]. However, the role of sphingolipid metabolism in 
GLS1-associated EV release has never been reported. Therefore, ceramide was 
added to LPS-treated BV2 cells with GLS1 inhibitors. The NanoSight results 
demonstrated a rescue of EV release of ceramide to GLS1 inhibitors, which 
indicates ceramide could be involved in the pathway of GLS1-regulated EV 
release. The connection of ceramide pathway with glutamine metabolism has 
barely been investigated. Research has suggested a potential role of glutamine 
and glutamate in the essential supply of nitrogen bond to lipid biosynthesis 
including sphingolipids. Whether ceramide could be the downstream or upstream 
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product of this pathway remains unclear. The association between of ceramide 
and α-KG or energy production is also understudied.  
 Further investigation is needed for the relation between sphingolipids and 
GLS1 levels. After the treatment of GLS1 inhibitors, the activities and expression 
level of neutral sphingomyelinases needs to be measured. The level of ceramide 
would be assessed through mass spectrometry, which will provide further 
evidence for the association between ceramide, glutamine, and GLS1 in EV 
release. The other components in the sphingolipids family, including 
sphingomyelin, sphingosine and etc. should also be assessed to uncover the 
potential pathways to link these effectors to EV release. Furthermore, cholesterol 
has been reported to be associated with EV release [222, 223]. However, the 
involvement of cholesterol in GLS1-regulated EV release is unknown. These 
further investigations can shed light on the detail mechanisms of how GLS1 
regulates EV. 
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4.6 Conclusion 
 In summary, the regulation of GLS1 in EV release is associated with 
glutamate, and its downstream product, α−KG and the sphingolipid, ceramide, 
which implicates the importance of glutamine metabolism and sphingolipid 
metabolism in EV release. This new mechanism will shed insight on the 
regulation of EVs and provide potential therapeutic targets for HAND and some 
types of neoplasms. 
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4.7 Tables and Figures 
Figure 4.1 
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Figure 4.1. EV release in HIV-1-infected macrophages is dependent on 
glutamine. 
(A-H) MDM was infected by HIV-1 virus for 6 days, and the medium was 
changed into serum free glutamine-free DMEM. Additional glutamine was added 
to the medium at the concentrations of 1 mM, 2 mM and 5 mM. EVs were 
isolated through differential centrifugation and resuspended upon the 
concentrations of whole cell lysates. EVs were fixed and subjected to negative 
staining using TEM under a magnification of 2700 X (A-D) and 42,000 X (E-H). (I) 
EVs numbers in E to H were quantified by manually counting from a total of 7 
random vision fields. Results are representative of TEM images and 
quantification results are means ± SD of EV numbers from 7 fields of TEM 
images. *** denotes p < 0.001 in comparison to controls. 
 
  
  131 
 
Figure 4.2 
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Figure 4.2. EV release in HIV-1-infected macrophages is dependent on 
glutamine. 
MDM was infected by HIV-1 virus for 6 days, and the medium was changed into 
serum free glutamine-free DMEM. Additional glutamine was added to the 
medium at the concentrations of 1 mM, 2 mM and 5 mM. (A, B) Supernatants 
were collected and centrifuged at 1,500 rpm for 5 min to remove cells. Samples 
were prepared for RP-HPLC and the levels of glutamate and glutamine were 
determined. (C) Protein lysates were prepared from whole cell lysates and EVs 
pellets. The levels of GAC and EVs markers Alix, flotillin-2 and CD9 were 
analyzed by Western blot. EV protein loading was normalized with protein 
concentrations in whole cell lysates. (D) Densitometric quantification of the 
protein level of GAC in whole cell lysates was presented as fold change relative 
to β−actin. (E-G) Densitometric quantifications of the protein levels of EV markers 
were presented as fold changes relative to that in mock-infected control EV 
lysates. Western blot results shown are representative of three independent 
experiments. Quantification results shown are means ± SD of experiments 
performed in triplicate (n = 3 donors).  *, ** and *** denotes p < 0.05, 0.01 and 
0.001, compared with that of the control microglia cells.  
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Figure 4.3 
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Figure 4.3. EV release in immune-activated microglia is dependent on 
glutamine. 
When BV2 medium was changed into serum free glutamine-free DMEM, 
additional glutamine was added to the medium at concentrations of 1 mM, 2 mM 
and 5 mM 6 hours prior to LPS treatment. (A) Cell viability was measured after 
overnight treatment using MTS assay.  (B, C) Supernatants were collected and 
centrifuged at 1,500 rpm for 5 min to remove cells. Samples were prepared for 
RP-HPLC and the levels of glutamate and glutamine were determined. (D) 
Quantifications of NanoSight NTA of vesicle concentration for samples from LPS-
treated BV2 cell with different glutamine concentrations. (E) Protein lysates were 
prepared from the whole cell lysates and EVs pellets. The levels of GAC and EVs 
markers, Alix, flotillin-2 and CD9 were analyzed by Western blot. EVs protein 
loading was normalized with protein concentrations in whole cell lysates. (F) 
Densitometric quantification of the protein level of GAC in whole cell lysates was 
presented as fold changes relative to β−actin. (G, H) Densitometric 
quantifications of the protein levels in EV markers were presented as fold 
changes relative to that in mock-infected control EV lysates. Western blot results 
shown are representative of three independent experiments. Quantification 
results shown are means ± SD of experiments performed in triplicate (n = 3 
donors).  *, ** and *** denotes p < 0.05, 0.01 and 0.001, compared with that of 
control microglia cells. 
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Figure 4.4 
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Figure 4.4. EV release in immune-activated microglia is associated with the 
level of α-ketoglutarate. 
BV2 cells were treated with 10 µM BPTES or 10 µM CB839 4 hours prior to LPS 
treatment overnight. BV2 cell regular medium was changed to serum-free DMEM 
medium when GLS1 inhibitors were added. Two hours prior to LPS treatment, 1 
mM of α-ketoglutarate was added to BV2 cells. (A) Cell viability was measured 
after overnight treatment using MTS assay. (B) After 1 mM of α-ketoglutarate 
treatment, Nanoparticle tracking analysis was conduct with 100 X dilution of 
collected EVs with filtered PBS. Quantifications of the NanoSight NTA of vesicle 
concentration for samples from LPS-treated BV2 cell with GLS1 inhibitors and α-
ketoglutarate. (C) Protein lysates were collected from LPS-treated BV2 cells with 
or without GLS1 inhibitors or α-ketoglutarate. GLS1 activities were determined by 
the enzyme activity assay. (D) Protein lysates were prepared from EV pellets. 
The levels of GAC and EVs markers, Alix and flotillin-2 were analyzed by 
Western blot. EVs protein loading was normalized with protein concentrations in 
whole cell lysates. (E, F) Densitometric quantifications of the protein levels of in 
EV markers were presented as fold change relative to that in mock-infected 
control EV lysates. Western blot results shown are representative of three 
independent experiments. Quantification results shown are means ± SD of 
experiments performed in triplicate (n = 3 donors).  *, ** and *** denotes p < 0.05, 
0.01 and 0.001, compared with that of the control. #, and ### denotes p < 0.05 and 
0.001 compared with that of the LPS-treated group. 
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Figure 4.5 
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Figure 4.5. EV release in immune-activated microglia is associated with 
sphingolipid metabolism. 
BV2 cells were treated with 10 µM BPTES or 10 µM CB839 4 hours prior to LPS 
treatment overnight. BV2 cell regular medium was changed to serum-free DMEM 
medium when GLS1 inhibitors were added. Two hours prior to LPS treatment, 50 
µM or 100 µM ceramide was added to BV2 cells. (A) Cell viability was measured 
after overnight treatment using MTS assay. (B) Protein lysates were collected 
from LPS-treated BV2 cells with or without GLS1 inhibitors or ceramide. GLS1 
activities were determined by the enzyme activity assay. (C) After 50 µM 
ceramide treatment, Nanoparticle tracking analysis was conduct with 100 X 
dilution of collected EVs with filtered PBS. Quantifications of the NanoSight NTA 
of vesicle concentration for samples from LPS-treated BV2 cell with GLS1 
inhibitors and ceramide. * and *** denotes p < 0.05 and 0.001, compared with 
that of the control. ### denotes p < 0.001 compared with that of the LPS-treated 
group.  
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Chapter 5 
General summary and future directions 
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5.1 Summary and General Discussion 
 Chronic neuroinflammation has been a hallmark of HAND, despite 
advances in HARRT. As such, a certain extent of cognitive impairment still exists 
and greatly affects patient quality of life. As the HIV-1 virus does not directly 
infect neurons, neuronal injury and synaptic damage are attributed to the HIV-1-
infected macrophages and microglia, which are believed to be the reservoir of 
HIV-1 [42, 224, 225]. Among HIV-1-infected macrophages and microglia, the 
production and release of the soluble neurotoxic factor, glutamate, is known to 
contribute to the induction of extensive neuronal injury and brain inflammation [46, 
50, 72, 74, 226, 227].  
 Over last decade, our lab has focused on the study of GLS1 in HAND. 
Significant evidence indicates that during HIV-1 infection GLS1 is upregulated 
and translocated from the inner membrane of mitochondria to cytosol [149]. 
GLS1 has also been detected in extracellular supernatants [188]. However, it 
was unknown how GLS1 is released from cytosol to extracellular space. 
Therefore, as discussed in chapter two, we investigated the role of EVs in 
carrying GLS1 as a cargo and as a facilitator of GLS1 release. We have shown 
that GLS1-containing EVs are able to acquire the GLS1 activity and generate 
more glutamate in the extracellular space or ex vivo. Using RP-HPLC to detect 
the level of glutamate in incubated EV supernatants, the production of glutamate 
was reversed by the addition of GLS1 inhibitors, which suggests GLS1 in EVs 
contributes to the generation of the excess levels of glutamate. The location of 
GLS1 in EVs remains undetermined. However, the detection of vGLUT1 in EVs 
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from macrophages and microglia suggests that during the budding of EVs from 
the plasma membrane, a transporter for glutamate is also translocated on the 
EVs. This facilitates the possible GLS1 activity in the EVs. The other contents in 
the EVs isolated from HIV-1-infected macrophages or immune-activated 
microglia have not been reported in the database for EVs, or exosomes online, 
which indicates the urgent need for detailed analysis of EV contents.  
 Interestingly, during the investigation of GLS1 release, we found that the 
presence of GLS1 inhibitors in the whole cell cultures not only affects the 
intracellular and extracellular glutamate level but also affect the level of EV 
secretion. A recent study reported that the production of EVs and their cargo 
could be interactively associated and regulated in retinal epithelial cells [228]. 
Therefore, we decided to investigate whether the EV cargo, GLS1 can also be 
involved in the regulation of EV release. An adenovirus construct was generated 
to overexpress both GLS1 isoforms, KGA and GAC in cells. The overexpression 
of GLS1 significantly increases the GLS1 activity and glutamate generation 
intracellularly and extracellularly. More importantly, the secretion of EVs was 
increased upon overexpression of GLS1, indicating the potential regulation of 
GLS1 in EV release. To further prove our hypothesis, we tested GLS1 inhibitors, 
BPTES, CB839, L-DON and CBX, a newly discovered blocker in HeLa cells, HIV-
1-infected macrophages and immune-activated murine and human microglia. 
The inhibition of GLS1 significantly attenuates the release of EVs in all these 
types of cells, where GLS1 also is released in EV as cargos. This regulation 
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prompted us to further study what can be the potential mechanism of GLS1 
regulating EV secretion.  
 The most direct link is the production of GLS, glutamate, which is affected 
instantly by the addition of GLS1 inhibitors. When different concentrations of 
glutamate were added, we did not observe a dose-dependent EV release. 
However, when glutamine was deprived, the EV level was significantly reduced, 
indicating the essential role of glutamine in the secretion of EVs. Glutamate is 
also known as a substrate that will be converted into α-ketoglutarate, which is a 
key intermediate of TCA cycle and Krebs cycle. Therefore, we added α-KG to 
LPS-treated BV2 cells with or without GLS1 inhibitors. The results showed that 
the α-KG along to control or LPS treated BV2 cells did not increase the level of 
EV release, where glutamine was present and glutamate production was not 
suppressed. However, when GLS1 inhibitors were added to LPS-stimulated BV2 
cells, the GLS1 activity was significantly reduced and the release of EV was 
significantly decreased. When α-KG was added to the culture, the GLS1 activity 
was still reduced, indicating α-KG did not interrupt the function of GLS1 inhibitors. 
However, the release of EV was rescued from the inhibition of GLS1 blockers, 
which suggests α-KG as a downstream effector for the regulation of EVs. Further 
investigation is still needed to test the level of extracellular glutamate and 
intracellular glutamate level to determine whether α-KG rescues the EV release 
by reverse reproducing glutamate or a direct effector on further downstream 
pathways. Since both glutamine metabolism and α-KG have been know as 
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important energy sources, the role of energy production could be linked in this 
mechanism. 
 Previously, we have proven that the inhibition of ceramide production can 
prohibit the secretion of EVs to the extracellular space and thus rescue the 
GLS1-associated glutamate-induced neurotoxicity. Ceramide has been believed 
to be involved the formation of multivesicular bodies [134]. EVs have been 
reported to be secreted in a ceramide-dependent pathway. However, the 
association between GLS1-regulated EV release and ceramide has not been 
investigated. Therefore, 50 µM of ceramide was added to GLS1-inhibitors treated 
BV2 cells after LPS stimulation. The ceramide tended to rescue the reduced EV 
release after GLS1 inhibition. However, the effect is not as significant as α-KG. 
One possibility is that α-KG could be more direct downstream of EV release. 
More important questions are what the association between α-KG and ceramide 
is unclear and what the link between the glutamine metabolism and sphingolipid 
metabolism remains to be elucidated. 
 With the evidence of the important role of GLS1 in the regulation of EV 
secretion in vitro, we also testify its regulation in vivo. Over last 5 years, we have 
developed, generated and characterized a GLS1-overexpressing mice model to 
better study HAND pathogenesis. These Nestin-GAC mice showed a significant 
increase of GAC and intracellular glutamate specifically in brain areas, including 
the hippocampus, cortex, midbrain and cerebellum but not in kidney. The Nestin-
GAC mice exhibited significant cognitive impairment in learning and memory. 
Increasing apoptosis and gliosis were also found in this model correlated with the 
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increasing amount of glutamate. More importantly, EV release in the brain was 
detected increased. This observation gives us a great inspiration that by 
inhibiting EV release and GLS1 release through GLS1 inhibitors, we can study 
the potential rescue effect from glutamate-associated neuronal injury. This in vivo 
study can truly provide an insight of the pathogenesis of HAND and further a 
therapeutic target and potential treatment for HAND. 
 Taken together, these results demonstrate a better understanding of the 
pathogenic role of GLS1 and EV in HIV-1-infected macrophages and microglia-
related to HAND (Fig 5.1). The importance of glutamate-associated neurotoxicity 
and neuronal injury has merged to be an important target for HAND patients. EVs 
are no longer considered as a biomarker or degrading mechanism for unwanted 
cellular compartments but present as a critical pathogenic component during 
neuroinflammation and immune activation. The understanding of the mechanism 
of EV release, GLS1, glutamine metabolism and sphingolipid metabolism 
definitely sheds light on to a potential pathway not only in neuroscience but also 
in cancer research and other broader aspects.  
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5.2 Future directions 
5.2.1 The role of EVs in macrophage/microglia-specific GLS1-
overexpressing mice 
 For this study, we focused on the regulation of EV release in 
macrophages and microglia in vitro. When studying this phenomenon in vivo, due 
to the limitation of our mouse model, we utilized the Nestin-GAC and Thy1-GAC 
mouse to assess the effect of GLS1 on EV release. These two models majorly 
overexpress GLS1 in most of the regions of the brain. However, to further 
investigate the regulation of EV release in macrophages and microglia, we are in 
the process of generating the macrophage-specific and microglia-specific GAC-
overexpressing mice to better study the specific role of GLS1 in the release of 
EVs in vivo. We will compare the behavioral impairment of the macrophage-
specific and microglia-specific GAC-overexpressing mice with that of the Nestin-
GAC mouse model. We will also examine the expression of GLS1 and 
intracellular glutamate levels in different regions of the mouse brain. 
Furthermore, the level of EV release will be assessed and compared using TEM, 
nanoparticle analysis and Western blot. GW4869, an inhibitor of neutral 
sphingomyelinase and EV release will be injected intraperitoneally into the mice 
immediately after the induction of GLS1 overexpression to evaluate the change 
in neuroinflammation and EV release in the brain. Furthermore, the GLS1 
inhibitors, including CBX, BPTES and CB839, will also be injected to further 
assess the role in the regulation of EV release. The levels of sphingolipids in the 
brain from different treatments will also be determined and compared using mass 
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spectrometry. These future experiments will further expand our knowledge of 
GLS1 regulating EV release in vivo. 
 
5.2.2 The role of EVs in GLS1 cKO mice 
 The previous generation of GLS1 KO mice was not successful due to the 
lethal developmental deficiencies in the respiratory system. This has caused 
additional challenge for further investigations into GLS1 functions and its 
mechanisms. Therefore, we are in the process of generating GLS1 conditional 
KO mice by crossing the GLS1-floxed mice with Csf1R-CreER mice. In this new 
Csf1R-GLS1-/- mouse model, GLS1 will be knocked out specifically from 
macrophages and microglia with temporal control of tamoxifen. The level of EV 
release from the mice brain will be assessed. Furthermore, we will cross the 
Csf1R-GLS1-/- mouse with HIV-Tat transgenic mice to investigate the effects of 
deletion of GLS1 in macrophages and microglia. Specifically we will be looking at 
reversing the destructive effects of the HIV-Tat mouse by assessing the 
behavioral parameters, brain inflammation levels, and electrophysiological 
functions. The release of EVs will also be examined to further confirm the role of 
GLS1 in the regulation of EV release. If our hypothesis is proven to be true, the 
newly developed GLS1 inhibitors from our lab could be a novel therapeutic 
method for HAND patients. 
 
5.2.3 The role of extracellular vesicles in astrocytes  
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 In the general microenvironment of the brain, astrocytes are abundant and 
play a crucial role during inflammation and neurodegenerative disease. In HAND, 
reports show that astrocytes contribute to CNS damage through the toxic and 
pro-apoptotic signaling to neighboring cells. During HIV infection, the glutamate 
metabolism and transportation is impaired in astrocytes, which further leads to 
access extracellular levels of glutamate. Additionally, astrocytes release EVs that 
contains ATP, lipid droplets, and miRNA that induces neurotoxicity. Our 
preliminary data has shown that the treatment of TNF-α and IL-1β on astrocytes 
alters the level of GLS1 and consequently the release of EVs. Interestingly, the 
GLS1 inhibitors, BPTES and CBX reversed the elevated EV release, which 
further indicating the regulation of EV release via GLS1. 
 
5.2.4 The role of extracellular vesicles in stem cell biology 
 GLS1 has also gained significant attention in cancer research as a 
therapeutic target [204, 229, 230]. Aberrant glutamine metabolism has been 
found in many neoplastic cells, and has been noted to promote the proliferation, 
transformation, invasion and metastasis of said neoplastic cells [174, 231-234]. 
Interestingly, EVs released from neoplasms have been reported to modify the 
cancer stem cells (CSCs) niche via the promotion of angiogenesis, tumor cell 
proliferation and metastasis [235-239]. EVs isolated from body fluids of cancer 
patients, including blood, ascites fluid, urine, and CSF, can modulate the 
metastatic niche through various growth factors and cytokines. EVs have also 
been utilized in the study of neurogenesis and stem cell therapy. However, the 
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direct role of EVs in the neurogenic niches has not yet been addressed. Potential 
roles include cellular and molecular mechanisms of exosomal regulation 
 A casual relationship between neurogenesis and neurodegenerative 
diseases has been revealed. In this case, the strong association of EVs and 
various neurodegenerative disorders, such as AD, PD, Prion disease and HAND 
provides the evidence that EVs may also play an important role in the neurogenic 
role in the brain microenvironment as powerful regulators, biomarkers, and 
therapeutic targets. Furthermore, our lab has reported that GLS1 is essential for 
the differentiation, survival and proliferation of human neural progenitor cells. 
This indicates the potential correlation between EVs, GLS1 and neural stem cell 
biology, which would be a novel future project. 
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5.3 Tables and Figures 
Figure 5.1 
  
Figure 5.1 Scheme of EV release associated with GLS1, glutamine and 
sphingolipid metabolism. 
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